<SEC-DOCUMENT>0001493152-25-014073.txt : 20250918
<SEC-HEADER>0001493152-25-014073.hdr.sgml : 20250918
<ACCEPTANCE-DATETIME>20250918163054
ACCESSION NUMBER:		0001493152-25-014073
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20250917
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250918
DATE AS OF CHANGE:		20250918

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enveric Biosciences, Inc.
		CENTRAL INDEX KEY:			0000890821
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				954484725
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38286
		FILM NUMBER:		251323848

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET RIVERVIEW II 18TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		239-302-1707

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET RIVERVIEW II 18TH FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMERI Holdings, Inc.
		DATE OF NAME CHANGE:	20150527

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SPATIALIZER AUDIO LABORATORIES INC
		DATE OF NAME CHANGE:	19950323
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:ENVB="http://enveric.com/20250917">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_ENVB_enveric.com_20250917 -->
<!-- Field: Set; Name: xdx; ID: xdx_049_20250917_20250917 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000890821 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000004" name="dei:EntityCentralIndexKey">0000890821</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="envb-20250917.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000890821</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-17</xbrli:startDate>
        <xbrli:endDate>2025-09-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90C_edei--DocumentType_c20250917__20250917_z27GIpBMDuDg"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--DocumentPeriodEndDate_c20250917__20250917_zcPP0YzbCgKc"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">September
17, 2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90F_edei--EntityRegistrantName_c20250917__20250917_z4mci55S8PVh"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000011" name="dei:EntityRegistrantName">Enveric
Biosciences, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20250917__20250917_z69BLVhGRAGa"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityFileNumber_c20250917__20250917_zJSzEj47kw33"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000013" name="dei:EntityFileNumber">001-38286</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20250917__20250917_zqVRi7AHBnng"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000014" name="dei:EntityTaxIdentificationNumber">95-4484725</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S.
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressAddressLine1_c20250917__20250917_zZpBkH2GfAp5"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000015" name="dei:EntityAddressAddressLine1">Enveric
Biosciences, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressAddressLine2_c20250917__20250917_zNJojQEqZUJh"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000016" name="dei:EntityAddressAddressLine2">245
First Street, Riverview II</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine3_c20250917__20250917_zXoQ3sKi6Ne8"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000017" name="dei:EntityAddressAddressLine3">18th Floor</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityAddressCityOrTown_c20250917__20250917_zu2dJH6jBD84"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000018" name="dei:EntityAddressCityOrTown">Cambridge</ix:nonNumeric></span>,
<span id="xdx_90C_edei--EntityAddressStateOrProvince_c20250917__20250917_zGzEcPEFSyK4"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000019" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressPostalZipCode_c20250917__20250917_zFnaZEwmO4td"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000020" name="dei:EntityAddressPostalZipCode">02142</ix:nonNumeric> </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of principal executive offices) (Zip code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_90D_edei--CityAreaCode_c20250917__20250917_zmPrjYjSBHD4"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000021" name="dei:CityAreaCode">(239)</ix:nonNumeric></span> <span id="xdx_906_edei--LocalPhoneNumber_c20250917__20250917_zV3aAmsFAWea"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000022" name="dei:LocalPhoneNumber">302-1707</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
name or former address, if changed since last report.)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--WrittenCommunications_c20250917__20250917_zWvyFjGp5mk6"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt:booleanfalse" id="Fact000023" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--SolicitingMaterial_c20250917__20250917_zu8TB6ydeBg4"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20250917__20250917_zKxa3xSyKnll"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20250917__20250917_ziIE5T9vyme9"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20250917__20250917_zq3NMrdg5Il8"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000027" name="dei:Security12bTitle">Common
    stock, par value $0.01 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--TradingSymbol_c20250917__20250917_z2J0l7Stuib2"><ix:nonNumeric contextRef="AsOf2025-09-17" id="Fact000028" name="dei:TradingSymbol">ENVB</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--SecurityExchangeName_c20250917__20250917_z775zTCLI1O8"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">The
    Nasdaq Stock Market</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_903_edei--EntityEmergingGrowthCompany_c20250917__20250917_zpEHeaqFyPAf"><ix:nonNumeric contextRef="AsOf2025-09-17" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.01 </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry
    into a Material Definitive Agreement. </b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2025, Enveric Biosciences, Inc., a Delaware corporation (the &#8220;Company&#8221;) entered into warrant exercise inducement
offer letters (the &#8220;Inducement Letters&#8221;) with certain institutional investors (the &#8220;Holders&#8221;) that held certain
outstanding (a) Series A Warrants to purchase up to an aggregate of 1,212,499 shares of the Company&#8217;s common stock, par value $0.01
per share (&#8220;Common Stock&#8221;), and (b) Series B Warrants to purchase up to an aggregate of 1,212,499 shares of the Company&#8217;s
Common Stock, both originally issued to the Holders on February 3, 2025, at an exercise price of $3.00 per share (collectively, the &#8220;Existing
Warrants&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Inducement Letters, the Holders agreed to exercise for cash their Existing Warrants at a reduced exercise price of $0.915 per
share in consideration for the Company&#8217;s agreement to issue in a private placement (x) new Series C Common Stock Purchase Warrants
(&#8220;New Series C Warrants&#8221;) to purchase up to 2,424,998 shares of Common Stock (&#8220;New Series C Warrant Shares&#8221;)
and (y) new Series D Common Stock Purchase Warrants (&#8220;New Series D Warrants&#8221; and, together with the New Series C Warrants,
the &#8220;New Warrants&#8221;) to purchase up to 2,424,998 shares of Common Stock (the &#8220;New Series D Warrant Shares&#8221; and,
together with the New Series C Warrant Shares, the &#8220;New Warrant Shares.&#8221;) The Company received aggregate gross proceeds of
approximately $2.2 million from the exercise of the Existing Warrants by the Holders, before deducing placement agent fees and other
offering expenses payable by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company engaged H.C. Wainwright &amp; Co., LLC (the &#8220;Placement Agent&#8221;) to act as its exclusive placement agent in connection
with the transactions summarized above and have agreed to pay the Placement Agent a cash fee equal to 7.0% of the aggregate gross proceeds
received from the Holders&#8217; exercise of their Existing Warrants, as well as a management fee equal to 1.0% of the aggregate gross
proceeds from the exercise of the Existing Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 12.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has also agreed to reimburse the Placement Agent for its expenses in connection with the exercise of the Existing Warrants and
the issuance of the New Warrants of $35,000 for its non-accountable expenses, up to $50,000 for its accountable expenses and $15,950
for its clearing costs. The Company has also agreed to issue to the Placement Agent or its designees warrants (the &#8220;Placement Agent
Warrants&#8221;) to purchase up to 169,750 shares of Common Stock (7.0% of the Existing Warrants being exercised) which will have the
same terms as the New Series C Warrants, except the Placement Agent Warrants will have an exercise price equal to $1.1438 per share (125%
of the offering price). The Placement Agent Warrants will be exercisable commencing on the Stockholder Approval Date (as defined below)
and expire on the five (5)-year anniversary of the Stockholder Approval Date. The closing of the transactions contemplated pursuant to
the Inducement Letters was September 18, 2025 (the &#8220;Closing Date&#8221;), which was subject to satisfaction of customary closing
conditions. The Company expects to use the net proceeds from these transactions for working capital and general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
resale of the shares of Common Stock underlying the Existing Warrants has been registered pursuant to an existing registration statement
on Form S-1, as amended (File No. 333-284277), declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on
January 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also agreed to file a registration statement on Form S-3 (or other appropriate form if it is not then Form S-3 eligible) providing
for the resale of the New Warrant Shares issued or issuable upon the exercise of the New Warrants (the &#8220;Resale Registration Statement&#8221;),
as soon as practicable (and in any event within 10 calendar days of the date of the Inducement Letters), and to use commercially reasonable
efforts to have such Resale Registration Statement declared effective by the SEC within 45 calendar days following the date of the Inducement
Letters (or within 75 calendar days following the date of the Inducement Letters in case of a &#8220;full review&#8221; of such registration
statement by the SEC) and to keep the Resale Registration Statement effective at all times until no Holder of the New Warrants owns any
New Warrants or New Warrant Shares. In the Inducement Letters, the Company agreed not to issue any shares of Common Stock or Common Stock
equivalents or to file any other registration statement with the SEC (in each case, subject to certain exceptions) until 15 days after
the Closing Date. The Company also agreed not to effect or agree to effect any Variable Rate Transaction (as defined in the Inducement
Letters) until one (1) year after the Closing Date (subject to an exception).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New
Warrant Terms</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following summary of certain terms and provisions of the New Warrants is not complete and is subject to, and qualified in its entirety
by, the provisions of the New Warrants, the forms of which are filed as Exhibits 4.1 and 4.2 to this Current Report on Form 8-K and are
incorporated herein by reference. The following description of the New Warrants is qualified in its entirety by reference to such exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Duration
and Exercise Price</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
New Warrant will have an exercise price equal to $0.915 per share. The New Series C Warrants will be exercisable on or after the date
on which stockholder approval is received (the &#8220;Stockholder Approval Date&#8221;) with respect to the issuance of the Series C
Warrant Shares until the five-year anniversary thereafter. The New Series D Warrants will be exercisable on or after the Stockholder
Approval Date with respect to the issuance of the Series D Warrant Shares until the 18-month anniversary thereafter. The exercise price
and number of New Warrant Shares issuable upon exercise of the New Warrants are subject to customary adjustment in the event of stock
dividends, stock splits, subsequent rights offerings, pro rata distributions, reorganizations, or similar events affecting the Common
Stock and the exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercisability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New Warrants will be exercisable, at the option of each Holder, in whole or in part, by delivering to the Company a duly executed exercise
notice accompanied by payment in full for the number of shares of the Company&#8217;s Common Stock purchased upon such exercise (except
in the case of a cashless exercise as discussed below). A Holder (together with its affiliates) may not exercise any portion of such
Holder&#8217;s New Warrants to the extent that the Holder would own more than 4.99% of the outstanding Common Stock immediately after
exercise, except that upon at least 61 days&#8217; prior notice from the Holder to us, the Holder may increase the amount of ownership
of outstanding stock after exercising the Holder&#8217;s New Warrants up to 9.99% of the number of shares of Common Stock outstanding
immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the New Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cashless
Exercise</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
at the time a Holder exercises its New Warrants, a registration statement registering the issuance of the shares of Common Stock underlying
the New Warrants under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) is not then effective or available for
the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise
in payment of the aggregate exercise price, the Holder may elect instead to receive upon such exercise (either in whole or in part) the
net number of shares of Common Stock determined according to a formula set forth in the New Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fundamental
Transactions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of any fundamental transaction, as described in the New Warrants and generally including any merger with or into another entity,
sale of all or substantially all of the Company&#8217;s assets, tender offer or exchange offer, or reclassification of the Company&#8217;s
Common Stock, then upon any subsequent exercise of a New Warrant, the Holder will have the right to receive as alternative consideration,
for each share of the Company&#8217;s Common Stock that would have been issuable upon such exercise immediately prior to the occurrence
of such fundamental transaction, the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration receivable upon or as a result of such transaction by a Holder of the
number of shares of Common Stock for which the New Warrant is exercisable immediately prior to such event. Notwithstanding the foregoing,
in the event of a fundamental transaction (other than for the purposes listed in the New Warrants), the Holders of the New Warrants have
the right to require the Company or a successor entity to redeem the New Warrants for cash in the amount of the Black-Scholes Value (as
defined in each New Warrant) of the unexercised portion of the New Warrants concurrently with or within 30 days following the consummation
of a fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
in the event of a fundamental transaction which is not in the Company&#8217;s control, including a fundamental transaction not approved
by its board of directors, the Holders of the New Warrants will only be entitled to receive from the Company or its successor entity,
as of the date of consummation of such fundamental transaction, the same type or form of consideration (and in the same proportion),
at the Black Scholes Value of the unexercised portion of the New Warrant that is being offered and paid to the Holders of Common Stock
in connection with the fundamental transaction, whether that consideration is in the form of cash, stock or any combination of cash and
stock, or whether the Holders of Common Stock are given the choice to receive alternative forms of consideration in connection with the
fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Transferability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to applicable laws, a New Warrant may be transferred at the option of the Holder upon surrender of the New Warrant to the Company together
with the appropriate instruments of transfer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fractional
Shares</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
fractional shares of Common Stock will be issued upon the exercise of the New Warrants. Rather, the number of shares of Common Stock
to be issued will, at the Company&#8217;s election, either be rounded up to the next whole share or the Company will pay a cash adjustment
in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trading
Market</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established trading market for the New Warrants, and the Company does not expect an active trading market to develop. The Company
does not intend to apply to list the New Warrants on any securities exchange or other trading market. Without a trading market, the liquidity
of the New Warrants will be extremely limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Right
as a Stockholder</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the New Warrants or by virtue of the Holder&#8217;s ownership of shares of Common Stock, such Holder of New
Warrants does not have the rights or privileges of a Holder of Company Common Stock, including any voting rights, until such Holder exercises
such Holder&#8217;s New Warrants. The New Warrants will provide that the Holders of the New Warrants have the right to participate in
distributions or dividends paid on shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Waivers
and Amendments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 45pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New Warrants may be modified or amended or the provisions of the New Warrants waived with the Company and the Holder&#8217;s written
consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forms of Inducement Letter, New Series C Warrant, New Series D Warrant, and the Placement Agent Warrant are attached as Exhibits 10.1,
4.1, 4.2, and 4.3, respectively. The descriptions of the terms of the Inducement Letter, New Series C Warrant, New Series D Warrant,
and the Placement Agent Warrant are not intended to be complete and is qualified in its entirety by reference to such exhibits. The Inducement
Letters contain customary representations, warranties and covenants by the Company which were made only for the purposes of such agreements
and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon
by the contracting parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 17, 2025 and September 18, 2025, the Company issued press releases disclosing the transactions described in this Item 1.01,
copies of which are filed as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    3.02</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
    Sales of Equity Securities.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued the New Warrants and Placement Agent Warrants pursuant to the exemption from the registration requirements of the Securities
Act, available under Section 4(a)(2) and/or Rule 506(b) of Regulation D promulgated thereunder and intends to issue the New Warrant Shares
and Placement Agent Shares pursuant to the same exemption or pursuant to the exemption provided by Section 3(a)(9) of the Securities
Act. The descriptions of the New Warrants and Placement Agent Warrants under Item 1.01 of this Form 8-K are incorporated by reference
herein. The forms of the New Warrants and Placement Agent Warrants have been filed as exhibits to this Form 8-K and are incorporated
by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9.01.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial
    Statements and Exhibits.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Form of Series C Common Stock Purchase Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-2.htm">Form of Series D Common Stock Purchase Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-3.htm">Form of Placement Agent Warrant</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form of Inducement Letter</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press Release, dated September 17, 2025</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-2.htm">Press Release, dated September 18, 2025</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within Inline XBRL document)</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    September 18, 2025</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC BIOSCIENCES, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Joseph Tucker</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph
    Tucker, Ph.D.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KwjAMhZ9g7xB6PXQd/uAuHTrEKTJEvK0uSnFrRlp/9ki+pXVDDIGQnPPlCBGKjJa6QobjvMhhj3VTKYdQ4AUZzRm9I12tE/CzwKu2jpVx3foDU/IMemYykCd/75wPbbFMIJoN5XQYjyGaJnIEu40IvnpK5qJLNE6rCpQpYcfUsEanuO0/7NWLDNVtl3RAtppMAnIQ9fIb4kjGsKWHehLfLOR5KoKwq0BkTPfGuxYvh+ZLwqLC2sfZnv538AHQ6Upl -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: right; text-indent: 4.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: right; text-indent: 4.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERIES
C COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
  Shares:_____________</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 37%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
  Date: _______, 2025</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SERIES C COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns
(the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the Stockholder Approval Date (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to
5:00 p.m. (New York City time) on the date that is the five-year anniversary of the Initial Exercise Date, provided that, if such date
is not a Trading Day, the date that is the immediately following Trading Day (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter,
to subscribe for and purchase from Enveric Biosciences, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______
shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share
of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Letter
Agreement</U>&rdquo; means that certain letter agreement between the initial Holder hereof and the Company, dated as of September 17,
2025, pursuant to which such initial Holder agreed to exercise one or more warrants to purchase shares of Common Stock and the Company
agreed to issue to the initial Holder this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stockholder
Approval</U>&rdquo; means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any
successor entity) from the stockholders of the Company with respect to issuance of all of the Warrants and the Warrant Shares upon the
exercise thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stockholder
Approval Date</U>&rdquo; means the date on which Stockholder Approval is received and deemed effective under Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, the current transfer agent of the Company, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice
of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be $0.915, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="width: 0.15in">=</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable
                                            Notice of Exercise if such Notice of Exercise is (1) delivered pursuant to Section 2(a) hereof
                                            on a day that is not a Trading Day or (2) delivered pursuant to Section 2(a) hereof on a
                                            Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule
                                            600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day,
                                            (ii) the highest Bid Price of the Common Stock on the principal Trading Market as reported
                                            by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) within two (2) hours of the time of the
                                            Holder&rsquo;s delivery of the Notice of Exercise pursuant to Section 2(a) hereof if such
                                            Notice of Exercise is delivered during &ldquo;regular trading hours,&rdquo; or within two
                                            (2) hours after the close of &ldquo;regular trading hours,&rdquo; on a Trading Day or (iii)
                                            the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
                                            is a Trading Day and such Notice of Exercise is delivered pursuant to Section 2(a) hereof
                                            after two (2) hours following the close of &ldquo;regular trading hours&rdquo; on such Trading
                                            Day;</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                 <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD>=</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">
                                            the Exercise Price of this Warrant, as adjusted hereunder; and</FONT></TD></TR>
                                                                 <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
                                                                 <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(X)</FONT></TD>
    <TD>=</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
                                                                 </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mechanics
                                            of Exercise</U>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery
                                            of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased
                                            hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account
                                            of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
                                            through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the
                                            Company is then a participant in such system and either (A) there is an effective registration
                                            statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares
                                            by Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume
                                            or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants),
                                            and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share
                                            register in the name of the Holder or its designee, for the number of Warrant Shares to which
                                            the Holder is entitled pursuant to such exercise to the address specified by the Holder in
                                            the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the
                                            delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising
                                            the Standard Settlement Period after the delivery to the Company of the Notice of Exercise
                                            (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice
                                            of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
                                            of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
                                            of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
                                            Price (other than in the case of a cashless exercise) is received within the earlier of (i)
                                            one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement
                                            Period following delivery of the Notice of Exercise. If the Company fails for any reason
                                            to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
                                            Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages
                                            and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on
                                            the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading
                                            Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery
                                            Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares
                                            are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer
                                            agent that is a participant in the FAST program so long as this Warrant remains outstanding
                                            and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the
                                            standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
                                            primary Trading Market with respect to the Common Stock as in effect on the date of delivery
                                            of the Notice of Exercise.</FONT></TD></TR>
                                                                                       </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; padding: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; padding: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice
to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall
continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such
notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).
</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding
Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in
one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common Stock
or greater than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary,
in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option,
exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the
date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder
an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date
of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within
the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive
from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value
of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental
Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid any consideration
in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which
Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes
Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function
on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable Fundamental Transaction
for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the 100 day volatility as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization
factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C)
the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the VWAP immediately
preceding the public announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental
Transaction, if earlier), (D) a remaining option time equal to the time between the date of the public announcement of the applicable
contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will
be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the
Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity
in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo;
under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of
this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor
Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise
every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations
of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities,
jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits
of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the
issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof,
this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, provides to the Company an opinion of counsel, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that the transfer of this Warrant does not require registration under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 10 Cleveland Street, Unit A, Summerville, MA 02143, Attention: Kevin Coveney, email address:
kcoveney@enveric.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any
and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally,
by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of
such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and
effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address
set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to
be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on
the one hand, and the Holder, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 2.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
                                            Biosciences, Inc.</B></FONT></P>

</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:
Enveric Biosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">[&nbsp;&nbsp;&nbsp;]
<FONT STYLE="font-size: 10pt">in lawful money of the United States; or</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin-left: 1.5in; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;&nbsp;]
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: _______________________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:_________________________________</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ex4-2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERIES
D COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant Shares:
_______</FONT></TD><TD STYLE="text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
Date: _______, 2025</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SERIES D COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns
(the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the Stockholder Approval Date (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to
5:00 p.m. (New York City time) on the date that is the eighteen (18) month anniversary of the Initial Exercise Date, provided that, if
such date is not a Trading Day, the date that is the immediately following Trading Day (the &ldquo;<U>Termination Date</U>&rdquo;) but
not thereafter, to subscribe for and purchase from Enveric Biosciences, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price
of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Letter
Agreement</U>&rdquo; means that certain letter agreement between the initial Holder hereof and the Company, dated as of September 17,
2025, pursuant to which such initial Holder agreed to exercise one or more warrants to purchase shares of Common Stock and the Company
agreed to issue to the initial Holder this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stockholder
Approval</U>&rdquo; means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any
successor entity) from the stockholders of the Company with respect to issuance of all of the Warrants and the Warrant Shares upon the
exercise thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stockholder
Approval Date</U>&rdquo; means the date on which Stockholder Approval is received and deemed effective under Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, the current transfer agent of the Company, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF
copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice
of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be $0.915, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="width: 0.15in">=</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
    applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
    Exercise is (1) delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) delivered pursuant to Section
    2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
    NMS promulgated under the federal securities laws) on such Trading Day, (ii) the highest Bid Price of the Common Stock on the principal
    Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) within two (2) hours of the time of the Holder&rsquo;s
    delivery of the Notice of Exercise pursuant to Section 2(a) hereof if such Notice of Exercise is delivered during &ldquo;regular
    trading hours,&rdquo; or within two (2) hours after the close of &ldquo;regular trading hours,&rdquo; on a Trading Day or (iii) the
    VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of
    Exercise is delivered pursuant to Section 2(a) hereof after two (2) hours following the close of &ldquo;regular trading hours&rdquo;
    on such Trading Day;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD>=</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Exercise Price of this Warrant, as adjusted hereunder; and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD>
    <TD>=</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise
were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by
the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant
in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale
of the Warrant Shares by Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations
pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of a certificate, registered in
the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of
(i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the
Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery
Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the
earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of
the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise
by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each
$1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise),
$10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading
Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees
to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As
used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days,
on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of
Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in
all other respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to
the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax
or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the
right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other
Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% (or, upon election by a Holder prior to the issuance of any Warrants, 9.99%) of the number of shares of Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice
to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall
continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such
notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants,
issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire,
upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for
the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that
the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of
Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender
or exchange their shares for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding
Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in
one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property,
or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires greater than 50% of the outstanding shares of Common Stock
or greater than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been
issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this
Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such
Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the
relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary,
in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option,
exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the
date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder
an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date
of the consummation of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within
the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive
from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value
of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the
holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental
Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid any consideration
in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which
Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes
Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function
on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) determined as of the day of consummation of the applicable Fundamental Transaction
for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time
between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the 100 day volatility as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization
factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C)
the underlying price per share used in such calculation shall be the greater of (i) the sum of the price per share being offered in cash,
if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (ii) the VWAP immediately
preceding the public announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental
Transaction, if earlier), (D) a remaining option time equal to the time between the date of the public announcement of the applicable
contemplated Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will
be made by wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the
Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity
in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing
all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements
in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental
Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity
evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account
the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock,
such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant
immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to
the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo;
under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of
this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor
Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise
every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations
of the Company prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities,
jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits
of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the
issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof,
this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of
this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay
any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not
so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer
of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or
transferee of this Warrant, as the case may be, provides to the Company an opinion of counsel, the form and substance of which opinion
shall be reasonably satisfactory to the Company, to the effect that the transfer of this Warrant does not require registration under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant
and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to
or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities
law, except pursuant to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and
the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 10 Cleveland Street, Unit A, Summerville, MA 02143, Attention: Kevin Coveney, email address:
kcoveney@enveric.com, or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any
and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally,
by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of
such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and
effective on the earliest of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address
set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission,
if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to
be given. To the extent that any notice provided hereunder constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of
the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall
inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns
of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on
the one hand, and the Holder, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)<BR STYLE="clear: both">
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
    Biosciences, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="vertical-align: bottom; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">Enveric
Biosciences, Inc.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">___________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">___________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">___________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">___________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ___________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _____________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory:</FONT> _______________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: ___________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: _______________________</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:</FONT> ________________________</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>ex4-3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT
AGENT COMMON STOCK PURCHASE WARRANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
  Shares: _______</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
  Date: September 18, 2025</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or
its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after the Stockholder Approval Date (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on
or prior to 5:00 p.m. (New York City time) on the date that is the five (5) year anniversary of the Initial Exercise Date, provided that,
if such date is not a Trading Day, the date that is the immediately following Trading Day (the &ldquo;<U>Termination Date</U>&rdquo;)
but not thereafter, to subscribe for and purchase from Enveric Biosciences, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price
of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued
pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright &amp; Co., LLC, dated as of December 8
2024, as amended on January 14, 2025 and June 5, 2025 (the &ldquo;<U>Engagement Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated
in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stockholder
Approval</U>&rdquo; means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any
successor entity) from the stockholders of the Company with respect to issuance of all of the Warrants and the Warrant Shares upon the
exercise thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Stockholder
Approval Date</U>&rdquo; means the date on which Stockholder Approval is received and deemed effective under Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, the current transfer agent of the Company, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or
a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Engagement Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted
by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless
the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records
showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice
of Exercise on the Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $1.1438, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="width: 0.1in">=</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable
                                            Notice of Exercise if such Notice of Exercise is (1) delivered pursuant to Section 2(a) hereof
                                            on a day that is not a Trading Day or (2) delivered pursuant to Section 2(a) hereof on a
                                            Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule
                                            600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day,
                                            (ii) the highest Bid Price of the Common Stock on the principal Trading Market as reported
                                            by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) within two (2) hours of the time of the
                                            Holder&rsquo;s delivery of the Notice of Exercise pursuant to Section 2(a) hereof if such
                                            Notice of Exercise is delivered during &ldquo;regular trading hours,&rdquo; or within two
                                            (2) hours after the close of &ldquo;regular trading hours,&rdquo; on a Trading Day or (iii)
                                            the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
                                            is a Trading Day and such Notice of Exercise is delivered pursuant to Section 2(a) hereof
                                            after two (2) hours following the close of &ldquo;regular trading hours&rdquo; on such Trading
                                            Day;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 95.25pt; text-align: justify; text-indent: -20.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="width: 0.1in">=</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> the Exercise Price of this Warrant, as adjusted hereunder;
and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD>
    <TD STYLE="width: 0.1in">=</TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> the number of Warrant Shares that would be issuable upon
exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a
cashless exercise.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Mechanics
                                            of Exercise</U>.</FONT></TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.4in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery
                                            of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased
                                            hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account
                                            of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
                                            through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the
                                            Company is then a participant in such system and either (A) there is an effective registration
                                            statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares
                                            by Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume
                                            or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants),
                                            and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share
                                            register in the name of the Holder or its designee, for the number of Warrant Shares to which
                                            the Holder is entitled pursuant to such exercise to the address specified by the Holder in
                                            the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the
                                            delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising
                                            the Standard Settlement Period after the delivery to the Company of the Notice of Exercise
                                            (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice
                                            of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
                                            of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective
                                            of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise
                                            Price (other than in the case of a cashless exercise) is received within the earlier of (i)
                                            one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement
                                            Period following delivery of the Notice of Exercise. If the Company fails for any reason
                                            to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant
                                            Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages
                                            and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on
                                            the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading
                                            Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery
                                            Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares
                                            are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer
                                            agent that is a participant in the FAST program so long as this Warrant remains outstanding
                                            and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the
                                            standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
                                            primary Trading Market with respect to the Common Stock as in effect on the date of delivery
                                            of the Notice of Exercise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other
respects be identical with this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by
its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x)
the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds
(y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection
with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B)
at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock
that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the
Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing
herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares
of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and
such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>,
<U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may
require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company
shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company
(or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to
other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on
the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by
the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;
shall be 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership
Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number
of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of
this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership
Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this
paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct
this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained
in this paragraph shall apply to a successor holder of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the
Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which
the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership
Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent
(or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such
Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result
in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in
one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the
Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater
than 50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power
of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e)
on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a
result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and
the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the
event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable
at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the
public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount
of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation
of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within the Company&rsquo;s
control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive from the Company
or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised
portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental
Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock
are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <U>provided</U>,
<U>further</U>, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction,
such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the
Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value
of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg, L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free
interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the
applicable contemplated Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility
as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately
following the public announcement of the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in
such calculation shall be the greater of (i) the sum of the price per share being offered in cash, if any, plus the value of any non-cash
consideration, if any, being offered in such Fundamental Transaction and (ii) the VWAP immediately preceding the public announcement
of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier), (D)
a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction
and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately
available funds (or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the
date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which
the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company
under this Warrant in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably
satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at
the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise
of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value
of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of
shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior
to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon
the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this
Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant
referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly
and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and
power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company
prior thereto under this Warrant with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and
severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions
of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant
Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) <U>Notice
to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number
of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of
all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall
appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Warrant</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof, this Warrant and all rights
hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant
at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the
form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon
the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant
or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument
of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant
shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender
this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant
to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this
Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and
shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of
this Warrant, as the case may be, provides to the Company an opinion of counsel, the form and substance of which opinion shall be reasonably
satisfactory to the Company, to the effect that the transfer of this Warrant does not require registration under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d) <U>Authorized
Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a
sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.
The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with
the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all
such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise
of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly
issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof
(other than taxes in respect of any transfer occurring contemporaneously with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant,
but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary
or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the
foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise
immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,
as may be, necessary to enable the Company to perform its obligations under this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e) <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York,
Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is
not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of
this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including,
but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h) <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any
Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service,
addressed to the Company, at 10 Cleveland Street, Unit A, Summerville, MA 02143, Attention: Kevin Coveney, email address: kcoveney@enveric.com,
or such other email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or
other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or
sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing
on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest
of (i) the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any
notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder, on the other hand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)<BR STYLE="clear: both">
</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
    Biosciences, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To: Enveric
Biosciences, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) Payment
shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrant Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4) <U>Accredited
Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act
of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ASSIGNMENT
FORM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U> </U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U> </U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature:_________________________<U> </U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address:_________________________<U> </U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
Biosciences, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
17, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder
of Common Stock Purchase Warrants</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Inducement
    Offer to Exercise Common Stock Purchase Warrants</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences, Inc. (the &ldquo;<U>Company</U>&rdquo;) is pleased to offer to you (&ldquo;<U>Holder</U>&rdquo;, &ldquo;<U>you</U>&rdquo;
or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company&rsquo;s common stock, par value
$0.001 per share (the &ldquo;<U>Common Stock</U>&rdquo;) and (ii) a reduction in the Exercise Price (as defined in the respective Existing
Warrants) of the warrants set forth on <U>Exhibit A</U> hereto (the &ldquo;<U>Existing Warrants</U>&rdquo;) held by you in consideration
for exercising by you for cash all of the Existing Warrants, as set forth on the signature page hereto. The resale of the shares of Common
Stock underlying the Existing Warrants (the &ldquo;<U>Existing Warrant Shares</U>&rdquo;) has been registered pursuant to the registration
statement on Form S-1 (File No. 333-284277) (the &ldquo;<U>Registration Statement</U>&rdquo;). The Registration Statement is currently
effective and, upon exercise of the Existing Warrants pursuant to this letter agreement, will be effective for the issuance or resale
of the Existing Warrant Shares. Capitalized terms not otherwise defined herein shall have the meanings set forth in the New Warrants
(as defined herein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company desires to reduce the Exercise Price (as defined in the respective Existing Warrants) of the Existing Warrants to $0.915 per
share (the &ldquo;<U>Reduced Exercise Price</U>&rdquo;). In consideration for the exercise in full for cash of all of the Existing Warrants
held by the Holder at the Reduced Exercise Price as set forth on the Holder&rsquo;s signature page hereto (the &ldquo;<U>Warrant Exercise</U>&rdquo;)
on or before the Execution Time (as defined below), the Company hereby offers to sell and issue you new unregistered Common Stock purchase
warrants (the &ldquo;<U>New Warrants</U>&rdquo;) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (&ldquo;<U>Securities
Act</U>&rdquo;), to purchase up to a number of shares (the &ldquo;<U>New Warrant Shares</U>&rdquo;) of Common Stock equal to 200% of
the number of Warrant Shares issued pursuant to the Warrant Exercise hereunder, which New Warrants shall have an exercise price per share
equal to $0.915, subject to adjustment as provided in the New Warrants, will be exercisable at any time on or after the Stockholder Approval
Date and have the same term of exercise after the initial exercise date as the applicable Existing Warrants being exercised (applied
ratably), which New Warrants shall be substantially in the form as set forth in <U>Exhibit A-1</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New Warrant certificate(s) will be delivered at Closing (as defined below), and such New Warrants, together with any underlying shares
of Common Stock issued upon exercise of the New Warrants, will, unless and until their sales are registered under the Securities Act,
contain customary restrictive legends and other language typical for an unregistered warrant and unregistered shares. Notwithstanding
anything herein to the contrary, in the event that any Warrant Exercise would otherwise cause the Holder to exceed the beneficial ownership
limitations (&ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;) set forth in Section 2(e) of the Existing Warrants (or, if applicable
and at the Holder&rsquo;s election, 9.99%), the Company shall only issue such number of Existing Warrant Shares to the Holder that would
not cause the Holder to exceed the maximum number of Warrant Shares permitted thereunder, as directed by the Holder, with the balance
to be held in abeyance until notice from the Holder that the balance (or portion thereof) may be issued in compliance with such limitations,
which abeyance shall be evidenced through the Existing Warrants which shall be deemed prepaid thereafter (including the cash payment
in full of the exercise price), and exercised pursuant to a Notice of Exercise in the Existing Warrants (provided no additional exercise
price shall be due and payable). The parties hereby agree that the Beneficial Ownership Limitation for purposes of the Existing Warrants
is as set forth on the Holder&rsquo;s signature page hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressly
subject to the paragraph immediately following this paragraph below, Holder may accept this offer by signing this letter agreement below,
with such acceptance constituting Holder&rsquo;s exercise in full of the Existing Warrants for an aggregate exercise price set forth
on the Holder&rsquo;s signature page hereto (the &ldquo;<U>Warrant Exercise Price</U>&rdquo;) on or before 9:00 a.m., Eastern Time, on
September 17, 2025 (the &ldquo;<U>Execution Time</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company agrees to the representations, warranties and covenants set forth on <U>Annex A</U> attached hereto. Holder represents and
warrants that, as of the date hereof it is, and on each date on which it exercises any New Warrants it will be, an &ldquo;accredited
investor&rdquo; as defined in Rule 501 of Regulation D promulgated under the Securities Act, and agrees that the New Warrants will contain
restrictive legends when issued, and neither the New Warrants nor the shares of Common Stock issuable upon exercise of the New Warrants
will be registered under the Securities Act, except as provided in <U>Annex A</U> attached hereto. Also, Holder represents and warrants
that it is acquiring the New Warrants as principal for its own account and has no direct or indirect arrangement or understandings with
any other persons to distribute or regarding the distribution of the New Warrants or the New Warrant Shares (this representation is not
limiting Holder&rsquo;s right to sell the New Warrant Shares pursuant to an effective registration statement under the Securities Act
or otherwise in compliance with applicable federal and state securities laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Holder understands that issuance of the New Warrants and the New Warrant Shares are not, and may never be, registered under the Securities
Act, or the securities laws of any state and, accordingly, each certificate, if any, representing such securities shall bear a legend
substantially similar to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; padding: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;THE
OFFER AND SALE OF THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificates
evidencing the New Warrant Shares shall not contain any legend (including the legend set forth above), (i) while a registration statement
covering the resale of such New Warrant Shares is effective under the Securities Act, (ii) following any sale of such New Warrant Shares
pursuant to Rule 144 under the Securities Act, (iii) if such New Warrant Shares are eligible for sale under Rule 144 (assuming cashless
exercise of the New Warrants), without the requirement for the Company to be in compliance with the current public information required
under Rule 144 as to such New Warrant Shares and without volume or manner-of-sale restrictions, (iv) if such New Warrant Shares may be
sold under Rule 144 (assuming cashless exercise of the New Warrants) and the Company is then in compliance with the current public information
required under Rule 144 as to such New Warrant Shares, or (v) if such legend is not required under applicable requirements of the Securities
Act (including judicial interpretations and pronouncements issued by the staff of the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
and the earliest of clauses (i) through (v), the &ldquo;<U>Delegend Date</U>&rdquo;)). The Company shall cause its counsel to issue a
legal opinion to the Transfer Agent promptly after the Delegend Date if required by the Company and/or the Transfer Agent to effect the
removal of the legend hereunder, or at the request of the Holder, which opinion shall be in form and substance reasonably acceptable
to the Holder. From and after the Delegend Date, such New Warrant Shares shall be issued free of all legends. The Company agrees that
following the Delegend Date or at such time as such legend is no longer required under this Section, it will, no later than one (1) Trading
Day following the delivery by the Holder to the Company or the Transfer Agent of a certificate representing the New Warrant Shares issued
with a restrictive legend (such first (1st) Trading Day, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered
to the Holder a certificate representing such shares that is free from all restrictive and other legends or, at the request of the Holder
shall credit the account of the Holder&rsquo;s prime broker with the Depository Trust Company System as directed by the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Holder&rsquo;s other available remedies, the Company shall pay to a Holder, in cash, (i) as partial liquidated damages
and not as a penalty, for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such New Warrant Shares
are submitted to the Transfer Agent) delivered for removal of the restrictive legend, $10 per Trading Day (increasing to $20 per Trading
Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate
is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the Holder by the
Legend Removal Date a certificate representing the New Warrant Shares that is free from all restrictive and other legends and (b) if
after the Legend Removal Date the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by the Holder of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of
Common Stock equal to all or any portion of the number of shares of Common Stock that the Holder anticipated receiving from the Company
without any restrictive legend, then, an amount equal to the excess of the Holder&rsquo;s total purchase price (including brokerage commissions
and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket
expenses, if any) over the product of (A) such number of New Warrant Shares that the Company was required to deliver to the Holder by
the Legend Removal Date and for which the Holder was required to purchase shares to timely satisfy delivery requirements, multiplied
by (B) the weighted average price at which the Holder sold that number of shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this offer is accepted and the transaction documents are executed by the Execution Time, then as promptly as possible following the Execution
Time, but in any event no later than 9:15 a.m.., Eastern Time, on the date hereof, the Company shall issue a press release disclosing
the material terms of the transactions contemplated hereby and shall file a Current Report on Form 8-K with the Commission disclosing
all material terms of the transactions contemplated hereunder, including the filing with the Commission of this letter agreement as an
exhibit thereto within the time required by the Exchange Act. From and after the dissemination of such press release, the Company represents
to you that it shall have publicly disclosed all material, non-public information delivered to you by the Company, or any of its respective
officers, directors, employees or agents in connection with the transactions contemplated hereunder. In addition, effective upon the
dissemination of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under
any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
agents, employees or Affiliates on the one hand, and you and your Affiliates on the other hand, shall terminate. The Company represents,
warrants and covenants that, upon acceptance of this offer, the Warrant Shares shall be issued at Closing free of any legends or restrictions
on resale by Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
later than the first (1st) Trading Day following the date of the public disclosure of the transactions hereunder, the closing (&ldquo;<U>Closing</U>&rdquo;)
shall occur at such location as the parties shall mutually agree. Unless otherwise directed by H.C. Wainwright &amp; Co., LLC (the &ldquo;<U>Placement
Agent</U>&rdquo;), settlement of the Warrant Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;)
(i.e., on the Closing Date (as defined below), the Company shall issue the Warrant Shares registered in the Holder&rsquo;s name and address
provided to the Company in writing and released by the Transfer Agent directly to the account(s) at the Placement Agent identified by
the Holder; upon receipt of such Warrant Shares, the Placement Agent shall promptly electronically deliver such Warrant Shares to the
Holder, and payment therefor shall concurrently be made to the Company by the Placement Agent (or its clearing firm) by wire transfer
to the Company). The date of the Closing of the Warrant Exercise shall be referred to as the &ldquo;<U>Closing Date</U>&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the obligations of the Holders under this letter agreement are several and not joint with the obligations
of any other holder or holders of Existing Warrants or other warrants of the Company (each, an &ldquo;<U>Other Holder</U>&rdquo;) under
any other agreement related to the exercise of such warrants (&ldquo;<U>Other Warrant Exercise Agreement</U>&rdquo;), and the Holder
shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other Warrant Exercise
Agreement. Nothing contained in this letter agreement, and no action taken by the Holders pursuant hereto, shall be deemed to constitute
the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption
that the Holder and the Other Holders are in any way acting in concert or as a group with respect to such obligations or the transactions
contemplated by this letter agreement and the Company acknowledges that the Holder and the Other Holders are not acting in concert or
as a group with respect to such obligations or the transactions contemplated by this letter agreement or any Other Warrant Exercise Agreement.
The Company and the Holder confirm that the Holder has independently participated in the negotiation of the transactions contemplated
hereby with the advice of its own counsel and advisors. The Holder shall be entitled to independently protect and enforce its rights,
including, without limitation, the rights arising out of this letter agreement, and it shall not be necessary for any Other Holder to
be joined as an additional party in any proceeding for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Existing
Warrant Shares. This letter agreement shall be construed and enforced in accordance with the laws of the State of New York, without regards
to conflicts of laws principles. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts
sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with
any transaction contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely
    yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Enveric
    Biosciences, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Holder
Signature Page Follows]&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
and Agreed to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Holder: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Holder</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Existing Warrants: __________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
Warrant Exercise Price at the Reduced Exercise Price being exercised contemporaneously with signing this letter agreement: _________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing
Warrants Beneficial Ownership Blocker: &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
Warrants: _______________ (200% of the total Existing Warrants being exercised)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
Warrants Beneficial Ownership Blocker: &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC
Instructions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Holder
signature page to ENVB Inducement Offer]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annex
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations,
Warranties and Covenants of the Company</U>. The Company hereby makes the following representations and warranties to the Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SEC
    Reports</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company
    under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year preceding the date hereof (or such
    shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits
    thereto and documents incorporated by reference therein &ldquo;<U>SEC Reports</U>&rdquo;). As of their respective dates, the SEC
    Reports complied in all material respects with the requirements of the Exchange Act and none of the SEC Reports, when filed, contained
    any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to
    make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company is not currently
    an issuer identified in Rule 144(i) under the Securities Act.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authorization;
    Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
    by this letter agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this letter agreement
    by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary
    action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in
    connection herewith other than the Stockholder Approval. This letter agreement has been duly executed by the Company and, when delivered
    in accordance with the terms hereof, will constitute the valid and binding obligation of the Company enforceable against the Company
    in accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
    moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws
    relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
    and contribution provisions may be limited by applicable law.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
    Conflicts</U>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company
    of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company&rsquo;s certificate
    or articles of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default
    (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any liens, claims,
    security interests, other encumbrances or defects upon any of the properties or assets of the Company in connection with, or give
    to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of,
    any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material
    understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii) conflict
    with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
    or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which
    any property or asset of the Company is bound or affected, except, in the case of each of clauses (ii) and (iii), such as could not
    have or reasonably be expected to result in a material adverse effect upon the business, prospects, properties, operations, condition
    (financial or otherwise) or results of operations of the Company, taken as a whole, or in its ability to perform its obligations
    under this letter agreement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; padding: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; padding: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration
    Obligations</U>. As soon as reasonably practicable (and in any event within ten (10) calendar days of the date of this letter agreement),
    the Company shall file a registration statement on Form S-3 (or other appropriate form, including on Form S-1, if the Company is
    not then S-3 eligible) providing for the resale of the New Warrant Shares by the holders of the New Warrants (the &ldquo;<U>Resale
    Registration Statement</U>&rdquo;). The Company shall use commercially reasonable efforts to cause the Resale Registration Statement
    to become effective within forty-five (45) calendar days following the date hereof (or within seventy-five (75) calendar days following
    the date hereof in case of &ldquo;full review&rdquo; of such registration statement by the Commission) and to keep the Resale Registration
    Statement effective at all times until no holder of the New Warrants owns any New Warrants or New Warrant Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trading
    Market</U>. Except for as related to the Stockholder Approval, the transactions contemplated under this letter agreement comply with
    all the rules and regulations of the Nasdaq Capital Market.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Filings,
    Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
    to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person
    in connection with the execution, delivery and performance by the Company of this letter agreement, other than: (i) the filings required
    pursuant to this letter agreement, (ii) application(s) or notice to each applicable Trading Market for the listing of the New Warrants
    and New Warrant Shares for trading thereon in the time and manner required thereby, (iii) the filing of Form D with the Commission,
    (iv) such filings as are required to be made under applicable state securities laws, and (v) Stockholder Approval.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Listing
    of Common Stock</U>. The Company hereby agrees to use best efforts to maintain the listing or quotation of the Common Stock on the
    Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of
    the New Warrant Shares on such Trading Market and promptly secure the listing of all of the New Warrant Shares on such Trading Market.
    The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include
    in such application all of the New Warrant Shares, and will take such other action as is necessary to cause all of the New Warrant
    Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably
    necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&rsquo;s
    reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees to maintain the eligibility
    of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including,
    without limitation, by timely payment of fees to the Depository Trust Company or such other established clearing corporation in connection
    with such electronic transfer. In addition, the Company shall hold an annual or special meeting of stockholders on or prior to the
    date that is ninety (90) days following the Closing Date for the purpose of obtaining Stockholder Approval, with the recommendation
    of the Company&rsquo;s Board of Directors that such proposals are approved, and the Company shall solicit proxies from its stockholders
    in connection therewith in the same manner as all other management proposals in such proxy statement and all management-appointed
    proxyholders shall vote their proxies in favor of such proposals. If the Company does not obtain Stockholder Approval at the first
    meeting, the Company shall call a meeting every ninety (90) days thereafter to seek Stockholder Approval until the earlier of the
    date on which Stockholder Approval is obtained or the New Warrants are no longer outstanding.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; padding: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt; padding: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsequent
Equity Sales</U>.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; padding: 0pt; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) From
    the date hereof until fifteen (15) days after the Closing Date, neither the Company nor any Subsidiary shall (A) issue, enter into
    any agreement to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock Equivalents or (B) file
    any registration statement or any amendment or supplement to any existing registration statement (other than the Resale Registration
    Statement referred to herein, the filing of any amendment or supplement to an existing registration statement for an &ldquo;at the
    market&rdquo; offering with the Placement Agent as sales agent or a registration statement on Form S-8 in connection with any employee
    benefit plan). Notwithstanding the foregoing, this Section (h)(i) shall not apply in respect of an Exempt Issuance. &ldquo;<U>Exempt
    Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company
    pursuant to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors
    or a majority of the members of a committee of non-employee directors established for such purpose for services rendered to the Company,
    (b) warrants to the Placement Agent in connection with the transactions pursuant to this letter agreement and any securities upon
    exercise of warrants to the Placement Agent, if any, securities upon the exercise or exchange of or conversion of any securities
    issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding
    on the date of this letter agreement, provided that such securities have not been amended since the date of this letter agreement
    to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities
    (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c) securities issued
    pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided
    that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights
    that require or permit the filing of any registration statement in connection therewith during the prohibition period in this Section
    (h)(i), and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through
    its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall
    provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the
    Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in
    securities.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify; text-indent: -0.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) From
    the date hereof until one (1) year following the Closing Date, the Company shall be prohibited from effecting or entering into an
    agreement to effect any issuance by the Company nor any Subsidiary of Common Stock or Common Stock Equivalents (or a combination
    of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which
    the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
    the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other
    price that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after
    the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being
    reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent
    events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects
    a transaction under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;,
    whereby the Company may issue securities at a future determined price, regardless of whether shares pursuant to such agreement have
    actually been issued and regardless of whether such agreement is subsequently canceled; <U>provided</U>, <U>however</U>, that, following
    the expiration of the restrictive period set forth in Section (h)(i) above, the entry into and/or issuance of shares of Common Stock
    in an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent shall not be deemed a Variable Rate Transaction.
    The Holder shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be
    in addition to any right to collect damages.</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Form
    D; Blue Sky Filings</U>. If required, the Company agrees to timely file a Form D with respect to the New Warrants and New Warrant
    Shares as required under Regulation D and to provide a copy thereof, promptly upon request of any Holder. The Company shall take
    such action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the New Warrants
    and New Warrant Shares for, sale to the Holder at Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states
    of the United States, and shall provide evidence of such actions promptly upon request of any Holder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; text-align: justify"></P>


<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAMBRIDGE,
Mass., September 17, 2025 &ndash; Enveric Biosciences, Inc. (NASDAQ: ENVB) (&ldquo;Enveric&rdquo; or the &ldquo;Company&rdquo;), a biotechnology
company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced
the entry into definitive agreements for the immediate exercise of certain outstanding series A warrants to purchase up to an aggregate
of 1,212,499 shares of common stock of the Company and series B warrants to purchase up to an aggregate of 1,212,499 shares of common
stock originally issued in February 2025, having an exercise price of $3.00 per share, at a reduced exercise price of $0.915 per share.
The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form
S-1 (No. 333-284277). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $2.2 million,
prior to deducting placement agent fees and estimated offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered series C warrants to purchase
up to 2,424,998 shares of common stock and new unregistered Series D warrants to purchase up to 2,424,998 shares of common stock. The
series C new warrants will have an exercise price of $0.915 per share, will be exercisable beginning on the effective date of stockholder
approval of the issuance of the shares issuable upon exercise of the new warrants and will expire five years thereafter. The series D
new warrants will have an exercise price of $0.915 per share, will be exercisable beginning on the effective date of stockholder approval
of the issuance of the shares issuable upon exercise of the new warrants and will expire eighteen months thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering is expected to close on or about September 18, 2025, subject to satisfaction of customary closing conditions. The Company intends
to use the net proceeds from the offering for product development, working capital and general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements
of the Securities Act of 1933, as amended (the &ldquo;1933 Act&rdquo;) and, along with the shares of common stock issuable upon their
exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the
Securities and Exchange Commission (&ldquo;SEC&rdquo;) or an applicable exemption from such registration requirements. The Company has
agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the
new warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Enveric Biosciences</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics
that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing
library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without
hallucinogenic effects. Enveric&rsquo;s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT&#8322;<SUB>A</SUB>&nbsp;and
5-HT&#8321;<SUB>B</SUB>&nbsp;receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, please visit&nbsp;<U>www.enveric.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&nbsp;</p></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These
statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking
statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology
such as &ldquo;plans,&rdquo; &ldquo;expects&rdquo; or &ldquo;does not expect,&rdquo; &ldquo;proposes,&rdquo; &ldquo;budgets,&rdquo; &ldquo;explores,&rdquo;
&ldquo;schedules,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates,&rdquo; &ldquo;forecasts,&rdquo; &ldquo;intends,&rdquo; &ldquo;anticipates&rdquo;
or &ldquo;does not anticipate,&rdquo; or &ldquo;believes,&rdquo; or variations of such words and phrases, or by the use of words or phrases
which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements
may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management
as well as assumptions made by and information currently available to management, including, but not limited to, statements regarding
the completion of the offering, the satisfaction of customary closing conditions related to the offering, the receipt of stockholder
approval and the anticipated use of proceeds from the offering. Actual results could differ materially from those contemplated by the
forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit
its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated
by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical
or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary
governmental approvals to market potential products; obtain future funding for product development and working capital on commercially
reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain
key executives and scientists; secure and enforce legal rights related to Enveric&rsquo;s products, including patent protection; identify
and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage
its future growth effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiberend
Strategic Advisors, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Irish</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(231)
632-0002</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dirish@tiberend.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Media
Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiberend
Strategic Advisors, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Casey
McDonald</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(646)
577-8520</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cmcdonald@tiberend.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>7
<FILENAME>ex99-2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enveric
Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAMBRIDGE,
Mass., September 18, 2025 &ndash; Enveric Biosciences, Inc. (NASDAQ: ENVB) (&ldquo;Enveric&rdquo; or the &ldquo;Company&rdquo;), a biotechnology
company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced
the closing of its previously announced exercise of certain outstanding series A warrants to purchase up to an aggregate of 1,212,499
shares of common stock of the Company and series B warrants to purchase up to an aggregate of 1,212,499 shares of common stock originally
issued in February 2025, having an exercise price of $3.00 per share, at a reduced exercise price of $0.915 per share. The shares of
common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-284277).
The gross proceeds to the Company from the exercise of the warrants were approximately $2.2 million, prior to deducting placement agent
fees and estimated offering expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. acted as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the immediate exercise of the warrants for cash, the Company issued new unregistered series C warrants to purchase
up to 2,424,998 shares of common stock and new unregistered Series D warrants to purchase up to 2,424,998 shares of common stock. The
series C new warrants have an exercise price of $0.915 per share, will be exercisable beginning on the effective date of stockholder
approval of the issuance of the shares issuable upon exercise of the new warrants and will expire five years thereafter. The series D
new warrants have an exercise price of $0.915 per share, will be exercisable beginning on the effective date of stockholder approval
of the issuance of the shares issuable upon exercise of the new warrants and will expire eighteen months thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company intends to use the net proceeds from the offering for product development, working capital and general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements
of the Securities Act of 1933, as amended (the &ldquo;1933 Act&rdquo;) and, along with the shares of common stock issuable upon their
exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the
Securities and Exchange Commission (&ldquo;SEC&rdquo;) or an applicable exemption from such registration requirements. The Company has
agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the
new warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor
shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Enveric Biosciences</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric
Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics
that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing
library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without
hallucinogenic effects. Enveric&rsquo;s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT&#8322;<SUB>A</SUB>
and 5-HT&#8321;<SUB>B</SUB> receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information, please visit <U>www.enveric.com.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These
statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking
statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology
such as &ldquo;plans,&rdquo; &ldquo;expects&rdquo; or &ldquo;does not expect,&rdquo; &ldquo;proposes,&rdquo; &ldquo;budgets,&rdquo; &ldquo;explores,&rdquo;
&ldquo;schedules,&rdquo; &ldquo;seeks,&rdquo; &ldquo;estimates,&rdquo; &ldquo;forecasts,&rdquo; &ldquo;intends,&rdquo; &ldquo;anticipates&rdquo;
or &ldquo;does not anticipate,&rdquo; or &ldquo;believes,&rdquo; or variations of such words and phrases, or by the use of words or phrases
which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements
may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management
as well as assumptions made by and information currently available to management, including, but not limited to, statements regarding
the receipt of stockholder approval and the anticipated use of proceeds from the offering. Actual results could differ materially from
those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric
to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the
value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are
efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates;
obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and
working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature
of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric&rsquo;s products, including
patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue
as a going concern; and manage its future growth effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor
Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiberend
Strategic Advisors, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Irish</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(231)
632-0002</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dirish@tiberend.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Media
Relations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiberend
Strategic Advisors, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Casey
McDonald</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(646)
577-8520</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cmcdonald@tiberend.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>envb-20250917.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaSOSbP9z5Z86ekhvWB2bQn6PywmTter9CN1CfNmsRIN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:ENVB="http://enveric.com/20250917" elementFormDefault="qualified" targetNamespace="http://enveric.com/20250917">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://enveric.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20250917_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="envb-20250917_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>envb-20250917_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>envb-20250917_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="envb-20250917.xsd#Cover" roleURI="http://enveric.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://enveric.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 17, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 17,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Enveric
Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000890821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4484725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Enveric
Biosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">245
First Street, Riverview II<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">18th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">302-1707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    stock, par value $0.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENVB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://enveric.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>envb-20250917.xsd</File>
    <File>envb-20250917_lab.xml</File>
    <File>envb-20250917_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "ENVB",
   "nsuri": "http://enveric.com/20250917",
   "dts": {
    "schema": {
     "local": [
      "envb-20250917.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "envb-20250917_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "envb-20250917_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://enveric.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://enveric.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001493152-25-014073-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-014073-xbrl.zip
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M8Z@(TT7GR->-W>#>3EM\XWZY-[#:+?\#4$L#!!0    ( -F#,ELIX>X!NBP
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MS0@9\"P9JR;P!$C-_74D-7T$L*14"2#;61>?OM"%4-X$A6>XG,1(?>HU2--
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MV)UME&3X^G>0IW"U7UW:$9.P"'NZH_@WIM5R>46@1XJH,K=NI)3I"$@J+?J
M2FO4X$>?,E)N**8C?C@&B;D,:3+D5$3K?;[&K=R! ?,N)>:F/?&_+D+ZY)J]
M4UZ]B8XXQ/(Z.D@ <H\94I=F2#WD.>1/=X[V?D5Z>/IA\/'@W?\'4$L#!!0
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M*^OLY"T0JWVQB=6N,%;[8A.KW9S%>Y[D@*^!0^4U.A$U[V2H.+3(<+#=9\5
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MI!AO,QS'8F\4A)I#<: PIT#A[K]%\[I([!,YEG(NS]$/X3Z3YR2!UA&L1A!
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MCTX<N=8%R*]-7PF'(0ENA&<;UY:ZP(B6]A7PIMLQF!D?:4*B 99CX*@9>C'
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M+1940O(5]K!-&$BP&18=B.&TK3:"(,=%?ALU,"B*QK)0R;Y*\1555P_V)YN
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MAGVEH>IZJ>]=9P8S?2M7J:,;#[BL2%]%[2-:]5H?&7-5NQ;'YG ^@DDF0@*
M%6R((&QO$C'.0D8-X74S9EE4QI\174$=2>V=#F6H/@\">*K9?:KS-]Q_WHBH
M2=4Y4E>\'$>.<>)'-N+W""8YEKLANJ[T(_L-!0DSI1.P:F+JV$0&3&MJUX[Y
M"T#6ZK\AJ*Q I1!,C!OEC&#'W0Y;:FY5NN]A'C8>SL\KFY?#1T9Q/Q:[DK*C
M]'2O^>$*5BB/-1HY3LT0W<I6E:=7;Y(HO[R'P-,*G2P_"W0Y(G>##:ULOWWK
MY-9G*-K<?B5M#M\CF&3*A^]=1-%_RZT:R4^P2K+>0AFM$65^:+ LNSUYA 3N
M](]4X!JZIMK7CHKD"'V3?@)/0B-5OHV8/>+PV;QI<>!UE3/XWPU_'O)\7I_H
M33EY\\ GLG5!_2BG6#)*4>BWE-PK>@]J;M_QE"R2T'FQ2>BL,J'SXDDE=)Z$
M;OLF;#<GI]W.;R>7I\<7%]YO[X[/CS^^=9/OV&QT$)!%4^T4RARCNHVN1>;%
MU2/35'7;M>G/W+ZAPSC'0CGDXL @$Y5KK;R7Y@*K_)"MDV9!>?9MC"ZC<6T-
M6]7 2T_=4<"MBOH'TC.6.E[\!0V*^P>EM8RR7O1YJ[NE05F;41Q^Q%4]_></
MSY9>0EM3K_^AD<<SCU.6P]T^G4RB'(G+X24';XX9=\DKL^B?@S@K!N1DP7M/
MT@%HE8.:_M:WXYI(DA;]G\@6N ^INO.(UFU +U8\HG62@_58ZI6R\,Q>KFC[
M;W4#-B+Q,$2"W)CO.RJU-E___QNQ60-[A*YU&N+C>]OJ&*\1B//2LH2^\]EK
M/CD2K7@4WM\MP;"?-L&P50;#?MH$PS;YF"5C? =O3C]>GAP>=SL?WWK'_SH^
M/SRY.&YR&!^^,GI(4Y@;&+C,7G8[$AIH\O8?[*S7)8:XXF#SUEZ/VTH0J@/Q
M? 9G&&'M/#,Z*4S\_\B?6B?,2A=/J\BKPJI-]?[!8 2OT61MF&*GRD33'RM.
MB3!9^MP18% JI0F)I=H$R",U*)HQ^_)E;&A^Q2A\)E1($ANVHAG*A>>?H3'?
MO5_, ^#._^Z3VGK6PSPPRX!T.44^;Y0%8I#&^EZ0,>S@8C:\GWWIO7QD*[&R
M[77G(685&H?P=4;Y+&#$T+5]5\?CO^K^^W_#7&J/<^J94D2?P6&G@@/-XH\L
M ]@%"OF(BE=>ENL%>O#KU" #S0L'ZLQ M0GAU-09M)5".RBH:%L15/MM/*-X
MW*9)X%:"%]-^H=J.8ZMCO[40C!^D>J#(=3$.OL3CZ;A]<'(?T:FNWC4U%BLF
MBPD).](R2NK'_-@T_];SGG>6</\#ZD!08.^!>C\=XA$(QIIFU;8$F!3'HM2@
M#[)L2#4,,=1&27;S_57KJGVH_YG_Y]'-]\&[)M(YKB+C%D.((K8076$H(HY^
MVS_T]D&_8=N14]([WUZ>?WA$LK0Y.X]B6K=LXV8?'\BT;MO';[^1CW#35FR_
MO9"*M@%3 L"U=4*TPNC.J ('VUACWN^_)2&R* ;F6[%\ZV\Y_0;-MS :$F\T
M&'?GNE.E=X2F,ECS5T2CKLJ]X4*],/6K^]RJ<._GY\^IDXT4T#TVX_G!FT)S
MH[3_=7'RR^G^Y:=SCJV_^_C^Z/C\O[_W%C[X',@]:#9,I%&!-1]]-%6/D;4!
M'G6K2E_PSX->G]<G;ZS2$%@GNPDX_2)C]HOJ^B%P_ YK^* 72PM3TR*M1* >
M]/(0!N-^U^=A+] 1V 4ONYU5K,.ZK,V#W(>[X%G^_K10+ YB1:W7!FCRX.WD
M>X&9[%^@/?SA^/2RVWG[\?S#!F.R&E$#@WZUF2ZL!+YDMBYXK\H_<1-JTQE!
M*N XST3I8.ZS-)D0M:^0[EHTN#O>4<:=4 K[6S;PH6"BH&]<;_RMUA6$OMOY
M=?_]IV/O_/CP^.37XR._>74U ;Z051ERJE*QK.61)EPK)#)19H]OS3:U=XN4
M _W\UV_BU:RJC$6&_>SN14RW2TK3".>;7/S,52W\NA5#?.O;<%TJ;59:?G?/
M2[C%0 (>X%D>IV5O76MKYHG]4]GWA[(G*UO3?>D+LSGD*QWK0Y"AA[35<LU3
M$.$K[OB-LM_8#ANU\D DZ&R4I7*6JKBR!R1-JW-0GK2TK:D.>)+#>JQR<8PM
MSG@D#]DL7I7&V0C1HS[%:SJL=9*+;X(+"%_R^"HY??BW[U72^^N[:^N[Q$]<
MPA[,N7](2_BD)(B[;TB+^8+'J9&#MV*[-I*WD;PUV*HU'=9&@KZ][E*NW>*H
MRHW@K5;POB$9VDH+)=8%'K9,K^E_O/(^3J@=WDOO?5"4&S#K?##KVL!-OU%-
MSX\''X]^QZ/XX[O+#^_?_']02P,$%     @ V8,R6[%PN)KW4   00P"  D
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MO)N(X)H,2UC[3\P*"@[BPMYYJI!>P@X$\A%0#1=!*K/K5PM4DO-2E9PEHCA
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MTRF59GH1O(O*:@.:NB5H:L.?M!;'X-6/!Z='OQ//S-N+]^]>_W]02P,$%
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MTU+_"5H."DS^C*7ZB 6]/-#O7275!5QHW ^2@'1GBT8$;YJ7+,U1^,&ORJH
ML2V-G<S3.'B\\\3<&#%NU'D!AP/F:V]4W9G$^WI+>]]W['X"8H?N<V?+DFPJ
M0U&5KND:96E&^@2(OHIT,-YOK$069:4*HQ5YHS2"#<4:?A#-9FF"INE6!)KY
M1"]SHXB ^".-, ,]O,1[&]X.O:GX>K:JY.NH^!"+=!TF8^E3WFR0^D\"&[5Q
MV-3_G,<EZV[R11:C/E5!$Z <4.,X5- B15GV7XG=N+I(\+S4W]39<SAA10PZ
M8\5SM9_F.2HAY\&K[7>@J ^CLCX\U'A))?WYZ:.=?B_J5.CA-GK\=.=AM\H_
M".$%--5OSP[^:Q][A7_Y1U,[=Z?T,D_G,%U7,6I4. )0C$'/ =5MX3Q;W?^&
MR<71UOJ#BAANCE$T3&&C;8U:]X=TN]]KGVE:;!E/RRM GD&;-(;2; RO>11_
MU+19,-D%[Y+L0_!V!M_(/MA"2S0*2C 74["9\N(<KO)_L5F 1^8<[(=KG)%1
MS .'I4+#=3+/1F)=3N0M^"UW:L#3/\UARG#&0*VTNWN&5J9J[[;G_1YWO<Q-
MIT/LP=9X0$(<E/@<#:$ O7&E*"114J XPH&PO0U-1AVV :GX[F&/,KRKXEE,
MH@F7K8C )(#Y*.,4+C"^/<[S?(PO@LM&! 0;YR6_:QK]F1>X39.,K[;8"@]1
MGN0\Y?.JK&#M<)IP"<&D@XL+M@GT!&9W5N&.4;U,+(.0=D@PB6,V\N./T%N4
M0O &/K[&O)E%B1%A\NOOY Z#@?V?!P^"ETF<CI\&[V#+/H,&0$""Y0L_? ;[
MG7;J4WR1J*//@M]PO\#7P8,'@H-X?GC\F_;R)O?[3_C9,"]@(YC/]M,(MMDN
M3%"9I\D8QKV<5UA>*:V-X,:)9B5T3?_F^7[;M'_K"FYQ\/KKE,83^H7QG#;=
MZ357LSNW.JO/@K/K&;Q_KXB&R>A9\ 9L3Y[Y-SG.YZ[[HQ_U5_B-=8"J^_/Y
MCS#M+2LPA//QX<$P!OD&;<]H5=U5^:D]* (=?N<OHGRL6^>=_T:WHS@ W@YW
M9IW(_&^4NJ65NCPJQN3U.22K(B_*AG;'ZA,^B')QK,\Y]\MW) WOP;#LXL]+
MN*S+LM\#3;*Y[*S/7XM> (HY7/51-2_&Z* ]!<LN(@N2OZ9_J-*+MB0Z ".X
M.J/L SHNR-E("B=L&Z.!HB(1S:L+N./_A5X-:*X <09;C"[;-+K"&[N(I^CW
M&Z4YJ,#/T/>B'F7L=(@?7.17\26[]-D8 7L"AH_>D@3-UT:/^&)'W7:(5DH\
M1?=TCO]8L3_!>$YJA4PKZ"#7Z-J_R*>Q3&=HOKN(4[@!8&D?S. R:WR?Y=D#
M6 Z,0T _X^DLS:_CV#@'Q,3B^;8:)2M+V%$PP1/5&EEKQ2[.65G#G\XNKDN\
MOX(A*$ZP3FD^DAA&5+'+G0XW*:?\B_,<9C5#?R7\2F:FN@85+H<?HZ;%TH$4
MNB+/DA%JKN,RX!@O]O,:E.]I&6PEV2B=DW:&RW.5H HM#Y7DFUYZTX#.#'9&
MFD(W2!%%=1O;!/L1%VD$QP@FOZ# C-@:&^FT-L-RPR33I"QA,[:XR'#3O<\2
M-").*[ 52]>_A*K\T<<1"*QS-G^XF<T>6)=A>7O V*[MBHGX+4LR0GV5) 2]
M5B/%?]G9WMFUQG%(F\2*4[@N2M)H2KN-P-[,U0P$,8)VJ_EN"E+>A WQU@"Y
MB4U@F)I<#;S[QIL]MR[#:M]SP1'<_K"#X*4MBC'N'V=3^+M/[^#3^;!,Q!\O
MV^DJGZ=CQ1O00Q+KIU T-I,'T8CT#KCC')R ZW$) W.EA@%ZZ_-YY> 20M;?
MXF&% ?@8KEE48DK^)<5 0[@Z^<DKB;X:;2XA=SX%+"4 [_=CE&=D"Z-+A8X)
M_%(P$.1FH7_R$:!_P_4<FM:O,# L@R\[1B_ CM"/6-^_77??#Y->P_W>WJAJ
M%^#.Q6TN;7@83]/NSX^\X'MH\#7%/)6+OHC/YZEHL6 63.?I.87R*P.1V&R;
M=1F6V38<=6P-C5( %(P_1)O@/6MQ-G3=5V ;E!?)+ 3K GI-0E(>X8MYGGF?
MP)V=@\W!O_\S!V$67,+HYJ@BD#"%9](D&B8IV3TCU2SX4=8ZS(?66J+0!G16
M'/P4]1ABO\N$0P4HZ 96X)(XO%:KZP.,<;-KUV589M=BU+O?VWW\N"GH*" .
MWW@BRH83Q$()?,Q3/6ANH_#4'.J@Z*]08%+!$1*X[ DA0I%!NJVQ,?B3;F!2
M6<1W@$*4/0<J0AV=-AJ#=M#:R8OH$LUXQ,E5$?DJ4GZFA*[@$&:Y("'CR20>
M5: Z.-W^3O;UXJC)PTV Y"X#) \W 9)-@.1V9+J5P,NIL%9S?;317+_'_6*1
M^[!A!+K?W#5T'4:*[(]*O<S=: /N%@MVZ=@XXG-X$Y7CZ)\"Q;#8$[SN^SV"
MEX">JVKF@%%#=&7;[C;\%X0 +.)R)O!S!&9'&0-[""]2@V'H#O<AZ":9HM\S
M61*B_VZV][H,:_'VKN=6.)*18%XF+MB:UI*4)HV'MI $XUAWQ(P3QI":S KX
M8[-QUF58=N.H%_2Z _!<F@?J<HC2KS!<&P:,GG<1@%%:YN((C=GC22%,%RF]
MH&G,0I4XK_A;QTX6%FW>C:A:KV'9Y"]&>':!&WS$0BM,%QIH1Q1O=L.Z#*NY
M&W@%VV,Y#50Z@U]+-YY1+MXT-X&-5:Y0!H^BS)^R#O?'Z5&P-\7D0AR:H]8=
M1+,$ 1@N^%J^^B7-APN_.25LAL&ELV13+(6)<JGC?4M=1*HREA2+<N<&M,\<
M!G-W26N;0W"'AX  -Z"ZG?LIB'((,-J).6T@[Z!O-HY.@?9Y45! 4*$]Z-NN
M&B%WC:M;HV/A#S:[:%V&97;1;[_OO6LJ<5\Z!ZB62$,ZW$TY0.,(AMZ5MG)#
M=M#262N;E*!-2M F)>A64X(N-BE!F]OLCFXSW3*M(%.'F8)X5.@X>'O<\&=<
MZ=9C_HK:QFA$=MLH(;Z3W;,X-/IH$QJ]R]#HHTUH]%Z$1K\Z$<I#0X2B9#_T
MP;T:[SV]_,"@<I:-LO\<VK5MR]XD6I6YXP@V3#8)*%THD>2:<ZY)B6-.HW&,
MV#O0F7(&&<'?$9Y7XSTKZ,]2&<JL[[V52DS(S/!G+'W8SJJQ?&&?QG&*Y&37
M->V.-<CQ'#3 ^&,\FN,(WAV^!'D^HPC$-*G(EH06X@=3L!;)'I&_1E45C2[P
MHAZ8L&M>B5EC^IEDZB>;(D4:O&9,,03H2(T5JOECCQ.JW_L=5&!I#JPAL(8+
M?'@K&1#CR];NP#/[<&ZV$OB2S*<Y$5C!X\XC)2$5BZ0DJX)HYN!'F-=Y&E=5
MRMK(.]@TH']O6<HN<E5:SJ[Q 'O I'8#E[3(A/LF#A\>:-&X4"7HRJ&3WB]:
MM"P3A[K/00]"!$2-/4SM+3 2.*", 6G.LY#)<8+D+0LRO/:SS0@U&I47,)U_
M+4K*RPM&%S'H!^,BNLK8GO9SBS ?+9AG*>5*DB\,?H__L@.=%3G8J9AKYW7/
M3AN8I<,8I@H-T=5&L V?P8,?'H#9 U($#@4_0P?7#-.8)0HA",'>U7G&K3^-
MQ_!7[,SY/,*S&K.U+>F=H#7@2^UW\!48S%$AMNE P:G-#L)YL:_%WE8('7!,
MKVO<Q^>R9_1($M-05%RW; M)RS1@"/B%IBZF>$[1$=E@HJMR7AL]ZO.L@D/K
MM TBS(BR<0N"00$+T26<=EH+ \1I8!NPK2'RS.D&H*6<S-,TI.,B>;#PII;A
M=0Z@'IN$!D Y2P6;>:7BH,"5>S3PC[:,Q0NXBRWK[!E?5)5Z 'F.74,65,:"
MTU#E:7F#TU^8JWE*/H@D,Q,K1CIY)SB-E(YNE6/\PDJE)::<Y\J0H#$> '\+
MAPADE$@<U\;O;%XZAR]@.DY^ Y%7!=$TAZWB\Q<ZY_&F1G''G]D5UHVBJ\BC
MP'QAXBXLXA'8$B7*,BLU;WZ%:58%+#G,S)QS#_Q7JFBE6X\H)(67SIYA7X#4
MO)9XI9"C:10GL\J\,Z-?@MZW_Z(V:@K5$]]J'#,=(_M8,O7[N7QW8(YE^54:
MC]$W2+]&(SA@NC/X+;MJC *"Z=ZEQ3M!2Z!+P$^BV458NX*,LM*R#^OSZ[-H
M]GM+[$\\E>85CGQ@I>8<ICQCU484(;HE*'>>]A7OM;**' _A)!HY,(.[(_?^
MMKP ZS^L84V--MQH?!P=U:#AA%V:5?4ON]N[CQ_]/;R)!K;!.-KLU9V3C6[V
MU^T.:T3[ZT!4S7[/L[.#XXF2-K EY2C=FD;)5*,8]W#0=*!C)V4ES,0DB&@G
M\<=TKX:*$@"Q2^#/.?-&1FP,5*+&:1S($XV$< 9M/XT[1*Y'\A6RG[YA0!*H
M:VB/T+AN2O9[QI9D5DJ<@N&U1+%)\LM9:&CJ&O!.W'"<IYX-37;JV$E%A28;
MUT._)Z/RE <,*244Z1[RG)%!BCEK>$?]]];>@_U!L/6/P?_@YUM[ X&UW1F!
MZS=V+E?RO"X_=,\1Z_F(F[Y(SS&[_"LZZCM\3J&$G>V_\:23\_6S&GIXRZL'
M.[->$L(K"F%>3 32__[I(VC9F;<Y#C] _)3\)WA,$<;0IO2Z+/,V^NPJW[Z%
M(%7^EOROS0P3U;K=0D,WC[72W#"2]2U$ Y'YJ_6%/!T(@U22?3^N?\C\3EL/
M5^@ M;E:+]S7F0H%9-K-XHSB\1,5YISX8"/U%SGT1@7ZED\RS\F8JW3DIYT=
M1#S ZTYL0N2;UZ=><HXE-)[$8Z0A<@D@TNBJ'!C:(;>@P6H],6Z\B^3\ L/;
M^\E8G&%M" K9Q#!YV2B909=JR!,'1K):/UHP)PY[F'[C%1E0)\553AN'5D@[
MK8H*V5JK](.O9^.M,\[=;B_L3=M4SMSGGUW7A3*>DUMBT68-=;<2!Y9.U8J[
MP\RK=9<3%]E-)\6^O X9PF.>P*9;K2-U*=HN'SM$7L.;T>977*4W25D;%)=M
MZ12L=R1494V\_>][*)9:*V>I7&&R6E]@%IZY=[@7W;U-'?/G)Z!^U$NFM6N9
M#Q[NT+/?B:+IE1+K+!#6KEBQ:JB#:Y;E:IWLN],']U?7!V_N\*UJ>@2L\8-'
M3<]C*0X4B<O1A?Z,G)!?K(K8[K(FV8/OR2:[1T?E'VMQ5#K=W60/,$G9,.:\
M7[S(,9/7R>*MQX,PG#+"\ :Y_"E[F+0^JAC2>%AN?=/:%3JK?!<.^F[L T54
M&1Y:,#$:CIWM+W=\=QYM+WO;/=K=_A*7W6),W>,-INXN,76/-YBZ>X&I^TJ.
M4CA9<)+.BQQ4$3P/>?$47=-5_,.+8S ^ZJ'((E:(<2*V0=3$HTC^#<;P\3<V
MVAKXP=8VH:TFT",P@;9^'AB+O4Y&I<A\RD)@U%"'SS\FD !W6N*B%?1)0J!Y
M9TOVOO BW*"LX0#87X4_CSYP[O<L+[G\FF)+N'&G3!KB<.XJ /8-7@OK?C1^
M>%$#$Z&>?@.:2%VZ-51@V!%AC>8@2Z-*L$46SG.9M!PKXRI 1,MF9ZW]T+Y)
M.^C;B4T]_%9C4V//OOH6HT[/W[]X'6-2?3(J5XS*^'C@IEECC9K[>0COQ:"^
M83_+MR)?=K<?WY)XN>42QLGV&DB70PF"K2Q<:LKY>Z1G\Z%%33#I"!/SVU1[
M@U!=K1L6M\8U=PB;S\D7BA!2KHJ J"I4S1.@#I9Y*6*LM2PQ%;1AYJB6K3@9
MMDT3742 487A(8:RFL^'44HVDKR*;26<JL.8[(X<S V/-F/58!H7\\5W2XO8
M%<P!P;P$9 F$EK&VS3B),JFKX\9C#W_?._!"L<DG1%IUV962(&(;$L/*[.$C
M@U->3OG1"7GEMO8&%F\&W6O'FZW6%PM.FZ$N7YG%=HD(6_8DER-8A$);.0HN
MVP[#I/N#UIR! HL@)>>) N'D]1[<S51I8):$%3<KYMUG65P\R"</J&U;ZZ'T
M0IB&:WHK@HF:$K-&PY"I)<P/5D0HF&SH*TFQ,:6EW. \6%!X;5 9+C# %&-H
M\UYDNYDS1@#9U7JBC6J3661 !LZRN2<Z-$C%;@=XK@D4JW3%>26< H,A=-?&
M]WEKML%X7.#BV+0@?]LD*QZ<#DR$-$I!=T7\+)M;ID"#U3JR( NOHX^K);&M
M/BT+,MX<WK]5N[TB?L.PG; /K<%%P+LPT!N^3J\YV.9+NQT&\\G&1DNBDBV-
M1]P^J AHY03E>:>S0DDZPQ@6QJUFLW)/.#FF0ZK7V6@5O.OX=)I)66&0%/(;
MF*I/T@X4HU*?;;][8: E"?EHS:+KJ4-VU<QM7*TO',O><BHQBK0;F4R7AH@?
M>,RJ5UVYI*M"!N\J\73%">$S:X$U-V/""#+O)=A%25H:UBK..%I1HN0V@]73
M3UOVKYO L4 Z&V3Y*OUHD1=A2Q;:++KV^TFP>MPX!(M(DW_.DS&A',?1-#I?
M54_"?4 (4@1BS>(L2JMKOFOC"([J7W;#G9V=ELO6F1G_>C0$5Y\*2^O&2BX-
M51N$T/$=RM[Y5 @6U;[$[25D3G]YZ+7' #SN%IQ1.!2M-V_0?CFLVAODT#)+
MTGP1+<"":TBR:IN/K;I7BM@!X$%_Y.! 0Z,$"XAZ.\$W227X S-ITBHCD]V]
M8C?.G1)G36,'I_WEWND9"O?S(IH&7ME3+Q46NU*ZV:BKGQVG@-IVL%=B/=.Q
M1#G"P*7@[E)A6BFX5[:YN/'2-LX1N1"IL%!-9>T]ZI#T)OY24^U7ZP;<%=.(
M[&D/R%S7 1JG.Z*JL9HJG+5>X)^D!;1<)U\$6+D\4NSGKXXR>;)!F=PERN3)
M!F5R'U F2Y_H6P^E)PG1-5G-(>>BVH8TL<45?%R#[3FD#$WZ"\[);.B=H2:J
M(I^'D#5&#G- OT<E0BPK1ATKZ#F1:DFO-YEE[?HYW%YVX$&,AELVHDN;^LDT
M1[X3"3E(-.\?/YYGEIVAIM BE$!LYAH]4BAFJ_MVGE*7<+/?DSNN)/@E;@=R
MK0FDTD'%W+L]>F^/'I^]$U1OJ8I>OW="N\PY9G7+%':<C;NTA$,D9G*SZ=F>
MWT(\3D1UU6U=6%,R\_W8+C,+'1?.E";EO::[W[O%O*][])*V*.[!."LE7H,R
M;']^_>"8>+%>PKY$BBM8:VPLO=:-LD10$5J(QN/$9:%A=Y9(6\LC4'=13'Q>
MIUL^'!VH=9]RQK(>"OU9-,PO_2S#*'."*W6*NH6G2]BE'0-<7/1N-,$I#-;O
M831C6.0?:M?2%A,:8=ZL<C33/$0C)9<V(9N!<CS4@I_<*JILDZ28.B$>PS44
M<I"F)/7!,[X<;Q@&"F$'E1-]-9%$-P-B':[>.B\#5AE%JQQ=4^S11*.0TQ%J
M+J/(L91YX[J><T>4^:XQC%^B>TS\82W;AJE[0EHIK'. M'+4SZV/ ]Z@M:ED
MRBNS.,P"LV5JMCM3/3*U54MM?V!B5$)Z5Y_L,G?8H>*/R!4.2[)U/7 ZZQ%0
M3)&K:Y9>XZO1@WMS H@[2U=1Z=&QM:M5"2%O,STLYC!9.L"*8<#"^H@9DGS8
M<&XPY\2L?!FC-H3&&Y(J8:<+B9AYU%<P1!"2C/+$/BJK(Y^JK?T!U:VO*)O<
M)8)2X2+A:_2Q4+B9N]-.&D4^&IB"2]C'\,_.R<.5$ZIP=V_"?$0,6;[(LQSG
M<<LCBJLY/^L1&+E<XS$=W6ZWL^U6^\[!O6JR>ZPB+^CLB\BG+ZM8S*/[/DTD
MC$#!U-B-V%DEW*R&0ZZU';RD^CD1M!&'!I8@?;;$<=[^EB+#4?LQ@C']99?]
MR7@1Y$1TIA=5W4N$^4)5%4^IG+$; .\29-0 %>_6J V)+G[ULKN1NKB#70R%
M-(#+6Y"HD9WE4$U@A03EFB!J5;R-FG*JSHH8>>*47>P>'YUX_CDXY1_I O$V
MF3"Z4;4TL+",$<0B!(G6KINW<D!4=CS#,A:9?-@.(9=\=*P]Y[6A6EO6_2ZR
M2A+"TKPLB4/R@KHB*&\>!B$>C.UH)*U10.D^CEW= H].$M>TBZ1RF=_@,*31
ME5#4XMQ2:0&1TJ%B-OH]"[<(D38C'F$.!?::H_8C]),BZRN#A++QC]3BGU2U
M@7 P<( F72Y,#P4QL6J6G#\][ET[EB:\ ]L1N**[3D//R7EW6^/N&]/4%SLQ
M?]HX,>_2B?G3QHFY<6)^SK#82'V3]WLO"S8NL,:=:#I%<#HJDAD;G+#A)O:1
MTCQ2XB.6PQPOW.9SYK85O4B+&->$;%*:_#P*V8EAJ^V)W4-&7\.H80W, ='Y
MM'-&IQ#GJ*,;MOE82<\EQ2QE]=OHMJ@C2"ZUPQSI7^#4//,$F[ZWL^/RD_J,
M&!46LF99"I5_ 2YA3&R$8>B=D\$&$3(_FIKOY-Y9_V%=LA/S !;M')[K]\ZB
MCS&723J2,DGBZW$ NG6PAQXLK!!@ +$C:K*F8RHRARU&MY!@%7TTW@RDVQZ1
MCYS(JJD;+>JIBQEN02^$R@<NQ]0,S-1_6E3V*>0P1DN[#4&R&*4J!YV_+>C/
MTJD.S_6,Z_C09[@H"C_#!8"5@4\N\JL8;GWZ(&!B906 71K40PN,F1'YMKN1
M=,=BS]H'4$NPO+J(R3LC01V)AS3-6W2^X20ZL-<]8I$F,?62RBA0X05;1\&O
MW^![E.K\VS!S&$XA]9?)7]!%H7Y(;E"3I0UD#V3V? K_FX!:GXA'$<R0Z1"T
MYQC-!]V:WHYT]J$T7,M:MB@L_+/FM*2*8T9/IZ)X,,4/QL2*EV,I3>'":^?@
MY[QN:'8BV!@<4G=F M=YY34%(PTLHZ3$&1ZE<40D9@KTQ&D2PX9,4ZE:9XK1
M#3KZ3-=0D6=@%RT.T6VD_YH,ZU)B6 =@H9-I#LNYG^<?RF;2$,6'T-/%5&>H
MEI1HIUY(]@[^BG,TB V?58UKR6\0$0SJ&8JITD1[G>SL!JM3O[<Q;&\P;/^V
M,6SOTK#]V\:PO0^&[=<CNHB)[=WW;#K6U"N;[-65I(D"5Z"/^&&GL&15H5EQ
MIQG0MZ$+9E=QPB)N>ZWX B_<&*I8ABDTNB<'/,6?+AU7"].HZ_R0TY$2H:FH
M:U07BO!<".#VTEJVJOP\)J7'Q*9JON0]T/E2=,F7MI0YJTGOXJ+$N ::OD1$
M@KHDLO:@8=O>:B!J8GNBJ7V5I 3)&URP[UY5%<EP3E/ZCME\W'@FINTI3UL6
MH[9*+";Y%9GO&!8L#8YIWSP1O+V">[:\2&;.MO+XDZE2U8 #-R;1)]=ZW45\
MGKMQBD;UE(Z89;V/K<H[*@O.S.!'+9-@4%/HIX^=P!>I)1WO]XCL.L]'1Z81
M!^:EG#'/6*+41ESM#GHHW8*)QVYQ(.7&:>'VV^GV*".O[MAGM#E%)[(\LQ"\
MC@.*Y;ENF'B[3VO3#U^TS;Y)^;%=*]"N@LNX="*G<Z=S6/4:>LL/57YO[2%S
MR+3]N)$3.3<QF< +R9@VO,D],@%;,%4DTX3(>R+GUP%31IG>%VYX,TKS\WQN
M;"KG5Z8HAG(1K3;/_=Z-$XVU&+&(4N")O43YONL!PU#+$SD'UJ,HPG06VTGJ
M(LD!M4V'F%&6CI#\7(S_#FZPW4=8)5R6"/IX$66@2.R-*F. %_-4-DIAV-1+
MCTJ]<H)P2<5'"<2JY2JKSUX#E2"4]9XOMQX1UQ(A.BXYN 15P*!VQ]A(CG0.
MSN)R0.]%RP3%!8S/I'_3K8P^"YH%-V0[1&A-VIA=F@SL!MSL[E4IX?K.G9=D
MS37F"U%+MOLRBUQ<L?AR7#Y.$](GV;-%'C29+JRLUSR>+=O;OP=Q#FZ6Y /.
M)5?/6X<,J_7/V:]R&' =@G%2CHJX#>>A"T<U/DN54:V)>'7@A3!4-.]O;V)I
MOWS"S+;(O<^<V'[O<V:6G(24'":8%).;MX0.$=;=;[I.I%IFN8N/@!8O416^
MEJN#\&:DS8U@*J+1M?'4>O/L 0DY$.]N[\C$8%@S0U#/O"1E#<],#">>9 _C
M]YREYD;N7.A)^20'%W.#M$XRT[EFN4"W^&&[<A%:11]]R 7**MPBJ[;#(())
MRNYGZ)00?C2P"].\K BC9Q+'DA%?>QE&D+@.!4M !R!V8!!P(>?6268S^[U#
M8MV(H.TB-FW/82N-L-E\#@M%GEO?*4]L'0?UW]50+XBFK/VF:@)*,1F.XH1T
M_2ZEU#E3*NGZ^#-].]I&!4V'8F1@B[I%L6JFG61O8_:UF[.IQP;;2CD1&R%E
M1=)Z$R[1ZXJ<]E[?C]DW9TN9KK1MVDY8A]U'BVZ4,"H'[8&UNC3#T*)U:G9I
M0_=:3KDM$\5>(0Z79(<1HAR>664&KISJ*VRU.P#5Q>+4L?2<"^_Q]L\__YO.
MP2K[T*MLM& 1O%!9K=5^;Q53RD6B"2I,SIV/? KIH$N6=,SX1OE[UZW3[SFF
M:TM]4%^*^N0,RUC#249E\RA2)O#:X.?FS-?,395E=S7]'7 OE&$N#T:<=H7%
M;I@II?O*49>>TS*A+GF]'>QES@*)SG7CNI@XP#!V&*%L8>:?=I^?OG_WHJR>
M_XA_4BTJ!P:OR,1%98K/6@=%]0&Y/JP503"JLBKF4DTW033JE(O84Y13H@\6
MD*$\&_"C!)8'A2U&P:KK+FY[;R8)EUH4;&YZ%6N#+3$05"/C*,5 1(S&>F.=
M+PH,8^>1YTC]$[13T.K#77W39F;SM-^S9@-7V9HB<3*K,0R-F<]D4L"PBM%Y
MA$G8=!S+I%#X)$PWW.PI5[NM.^ZLD<)KXY)4.44DU6RI+Q/M-N;(@.:P!_#V
M"R=9X.Z3W[ZQ>HF+HSI_WT1U[C*J\_=-5.=>1'6^RG%&K@Y-A7G$01L,G\/.
M1LJ2/8/%*WV:W_LP]'L:HXLH1B=I-(<))3*,V=X_G:5)>S9OJ,7A*64=[O@T
M;CA@'#61"Y3.D#0K8M0$UPZ.L[$74J/+&ST;Z/6R1@Q>ULZ_2RH@9[1(-(!\
M_;1P'.>2_)";OSG93H[YI1DAB=-RO^<UNT6J#+NCH\L\&:M".\[GPRIT@HX:
MP1%;MRML$]<A=^V&AT'C@LY/\8ER/N39*Y>QU4"AHL  @A&+AFT5<HU$]!L/
M08LIO60^3)$CEQ7"5@J,5/+:E;@O!BN\O)PB>T#;VZE(X^6 YX,J:8-VF49E
MR=P(XMOSC)':LOB3/(IF"8+5N*-UHQI= ;XOD+U>'KK7HCD]('#D(:"%25.,
MIKB(JMPA&%S*BMWBB!J9^&B"S(MK,RV:,-EE:DD:+B.H+\FE[OE%V4>>Y>1#
M7+EGBPT\^U+K&C5-DDU/*<C+Q24M A44<#8=Y%U:SXYKH:N)VR0=;*^)I[X%
M#BN"><86P9B-/@<S3I!='VCE6#U8+L;TD:@@K<G7G!F.8Q+?(V4[3S ^V!JN
M<)!C96MA=G82.S+2$XA4!72%7O5[]@'J68-I460*>RM9&$0J>XOX@7\DOQ,K
M9?V'->2[?3XL2<NOE* C> O; 2&Q92>/@3TB[5P;=#(HXL#2RE$'W!OMG%AX
M0I7O*(KB-"T9?-,5U*9-QQUUDT9*=OY?";5/Z+E/18L00[XB@#&6UXO4NR('
M4P\=1^C[/=K9BZ1TY7DWWVEG+--)2QZ^2RE22X&)1@+;-MDWY&^!";& '_4[
MU%X6UB1@[>MF-L[(YD/+:\=:I5B>P-1H\JPM!S;A5JQ8IV@SR+9N^;ZEL ;L
M<S'6W>5Z4-SK@;U&CO>;XREU7,02SLY!VWVI_F]\)\]6I/L">:-!^<P,1\$Y
M^]O5<TF^>V5?;U^=G(@]T,5*W]<:#NW;7>=[^];LFG\D$N?8K1-[:.DQ.=@6
M]3;84O=Q&$A2A294M*#:FH'B?L\F*"N_)-\KI(\UWRA8(!@5:%5Z_\@N9%^T
MA@)OC,?6CIE>]>J3=?/-_*ZU=<L2M-)PMXCCI DF,?/8&4I$JT5&US[GM5<-
M;"WOQ5TR*A(=5)SA87Q-MH<NO$PC^: E8P<%,>U&7EGDD*Q,4KFDG/"*,-CD
M<U?ESLJ$+6?K;[2!)88U(FW@79&#&H 7XZ%K4[,B<#BG1!FSA1JDL+Y=K\07
MM<CN&$VX(N;R#E+&L&'O>QHM73JX0^$RCE$Z>1J 7%[. Q2*N%%>AIX)6\V+
MS#41/<>#@\1KOW)X#*Y38B(LTZ4Z'>JHE] J(_CMC*\[VZ7(3 HT,L-0^&02
M-NS?$$,<2E /=B*NPSG%,T)"8W'*FO.QTQ5);'((DP8^FY"[!7Q=QE7HR(Y@
M2\8O4^(&IE$J6Z"-P-.Z&/AO$M)NO_1"PC2L)H#,2SPF5<=I3_!XT.J-:L^B
M6[=#ZUE0-OISU9Y6-.@RX<D;U)[)0K6G,?4KZ32"%OL4I2;HU&GL8DH N[D]
MMI;-%%U*L0ENU&N\EW=K-;@[/D>M"5;2:NH'QE$@.#%2^M:EVRQP55).0$VS
M6?"Z@8W+6W >?H_>9>=7-ZLUW%>3[>QJ.<$G*SD2IOW6M)QOR_.Q.#[[\R8^
M>Y?QV9\W\=E[$9_]:D=Z3'K^RWDVCJ:4NM_OG5D-4,-Y*X;P0@KA>=$49FY(
MKQG,H_\B'1!!G:C],TB5X<F.%EJJ0[KD'.F88E.,F:;C;QSEKG%!&"%Z%ZE3
M;@9;:(OU.*A7_ .=GPGH0T5WA_W.H-<DA*U&NFN:C) I ^\6I6\(#4%"R-!.
MOK1<L\:4;,>+E2@?T;^.,UEQ&HWP<C@&#R*99-(B,"$*@82VS9V&[)PU< <4
M.LQ]$^IEI0SD$Y[D6%'>_,F6(OR5[<:;07>6J?J2:K\^[QKK?8ZRUU#QI-XA
MJS#H!+8=<[H$;TLL)=RDU:HBVI_<<?6BPF'J9$4C3"ZRL56G3^<@%2LE_'BR
M8V"/;KRK'DF6WY#%X?WH,B= \@ST3,/Y.N(?:\RY%GVD0.?=G*"&T0B?Y,5Y
ME"7_<L(X8OF:S]JPG7QJ<)'G:9EK2-(N4&/1#=;<#6[;@!01;6IZ')U<9[E9
MS[]YA3E.O.3LD89WT_21I)E/IYQL8FUX'JTY0526QS>JA_,2 ^6E%R5K2>2K
MDROZ"Q(VEH-]  _(!V %8JN%/]"4&?=P\F;%_!!X6/-ZKU +QGP TI?;'Q?O
M2KG4\>B*&!>=OW;/B4E 6W10@BWR(+AN"N<N"VI7F1]]D; *VVH:]>I&5+0X
M)]H8X"DDZU3]\IFO.ZEGK<? 9\&M,:0FN:&\S3%-J(A=2J>.H9N:$6T4P#>[
M'U#"N,A>O'S$.&[W: SJ>1)=&X'[87&N*%!H@]4)>/*B(2"1%3TQ)3S+>7')
M6'+G9S:!70.6$4&[X8Z/I>%:Q&XOA5V)H )XC_.85U68EYC6"ZU=JE7AFKL=
MB\"P$!?)N\0,62;E11EU[7MD86=67O3@IC7WD[GH\!HOB,_;UP X+,+51#.4
MZT52 WHH+M\,M&/E^CTMH<?Q4$.UV_&\/8L^@QI>$2SNFZBEF\Y>-O93K S0
M6UP>+<.'?HJ3H;.?&5T36+*1NBO@?4E14Q<%YUF"G+E$&]PLRCA!90ZE'=[=
M,+;,5GOI>"&!^A:I;(B%ETRIBYS&8#+&Z[<UA4>-0L;N/%.GDP;6.9GM?J^A
MOMZX?AM]Z-P?2:7O+NU]T.FKM?4V%RTZT3?C"3-7(31*?,Y.GA=H&,6U4M*!
MAG9IN-<6C;YILJCP/$*OWW4+BT6M"%&]VON,V_:2BUUK#[K*%PUJ3S@H4K D
M(>_1#N:LE.SU#W5HK"PYI[M3#(G+&'6NPG$0*WBO+<DQ;Q2M[&A]$+H%B]Q%
M+/*INXFP>G=TW<P8-.R?='!(SS0TH.0 )#?4Z0B9/$MV<[5-?UXCK?!8(;J2
MDO-FF4YW8AEXL6 +-CD1@PY*Q,4K) P#3O7<6L(K)]44>>I&)*@**DKNRP9N
MU6R\_3SB6L>'I(SG1=FB8>49129:86]F&4VN==>9,&*ANIZ1JH]Y3!24\Y4!
MR1\UCUN<X< <G[9%SQML'[!UN\B"M-@F,Z>062T9642L*7NK2]36U%^OX(1-
MC.KRYX1.AGY4U89ON03,]/@Q2S'VC"%3:2B*M!1MM[/O(%8*5U"+C*ZO*-]]
MD<AK^CB7)+-1_0J\8>R+#P2%?B;S OMM3P0>B"4G'X>#.UW7$&\U7$*>IUI7
M%RH)8G-UO5>Q89:0@8P'<V>*A>3AF)L7 RN2C<\EW<[SYBQWS0UN&M>VF^K;
M/#>MY5H=5<43B)X>1XT]T,;>LEF#JA/52LW'<6I+OQ@Q(7UY^YN^4SD\L=7]
M-,]1&0>;_-7VN^U@R^VY?.6: ?V>F]!MM*<Q1^O;[L";+RPFKY%1&%H$)E,P
M:AWR#D18?>/#@TD1Q^C @'Y@#CT%_2GE$JE8QLY]]G[[=!M>)+CQ0N#&5*2:
MJHA[MQI=^L.XNHKCYAW4?2%[H$2/:J)KM!KZ.W.L 2X(16P'&5$/$]W"98YJ
M;"H9&;:KNSND?CC?<[)Z8^E__>VL?;6#+6<9Y]C&O[CJRJ.?GG V+M$VJ!<,
MRSGEQ<!9<)>-P+/#[!%:/&_!BM,6$J<#7S=CS$*ES4)6PTP+9'#EY$2+0[G,
M/QZX7]TPT!-UV"/OKZYUK5'_PC*%T[4>U"R=.P=8X\19GCU@G=^3B$X9J7JK
M"^U6P[N%+Z(:YRZ$P1)"=<RY\2FMNE>W),S\:0>;X\Y1D29Q@8DYAP,& *I"
M*'X9.GFW<197'1XGA+2=19[P(Q0Y_XH+S.CF@C9#$#/YE62?6][H+@5)+S!*
MH$!0$R*T#'<T1C?<HV-KU<"9'3/ R_%)>AMIX*JFJ;N;)Z@Z[*L#%DMS^XXO
MHXAJP0!O<X%\EZE>P9YI(Z7D(GWB"I&;-^:;=Y&I&VAI+-]W(.JX=7FAK]OW
M8=4O>,]YA7Z3$H83NSPI$F$B#Z%3O\K7=OH]+N+D.Z*6J1U82Y(9#_RX@##"
M&.\Y49.1!LJ85XJ%C6+K[$ /=22U]3#H4#?:Q@W3H^[IG&>.YP24A>AZ$"SG
M-S/)-&@/\-*TUU7KK ]G@B.,7'$F,U)'R76G#J>EHR3)3.8.=0 D=J!3Z </
M%=77/J6:P60IZQ.B'O6\BZPI^'I%F^-2(A2:]Z?V:5,/%1Z:640>*#X+ S?5
M4MU&-R+L6#4R[E@O>ZRI02Z'LUOHY%QNE[#?6<(N#O"/+U0!U3%#G?\Z?L#P
M8YGW=*4L;B'C9A5]H-P["G3#89QG6FRZX?M;,*OND;SQ!'BW_*(>AC6^()/Q
MUQB*P;?7)H/5 X/P8Z48?PXGO'(\G3&(Z7P*U^&EM<A=0>5I"0GEVAE/G"?>
M%QH\LK)Z3*Q("CR)M."TJ2A@3BR1(%XDQWC-%[H!&\?*>LS'8TL3@[JMW@W&
M </6CQ7G)L05;)4Y&\%LB6=C)UG1[66QTK2%' FC:B)4!\'<#_5UPF *: 2%
M8[NT=UX3-B<D5,LJCFC(])ZZE2X;MC%C\+?:9^2A_C-/T-7).E&)'49).@@_
MM:' :R=P*=\L]9/9]3Q!'$^DR(&'&= QB1@2V.)J'=/X ZL!2][]_@M;- $S
M+$9>"PMW6<?\FV/^"9,(PD-G,214-@5/L0[+6#GS]#4,Y.:0%.G#+2GX;5$$
MU\V(WPNJU,R'56SL]>)I-GRUI,(ZC6JHZQ@SW4,V6UM<)9K#O50D_XK'B^*
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M37);ZKTC\;Z@RZ77YS;YU4HS@'O]NFTBE>V@2<7A" E-U DE:=">[Z)^2"D
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ML6OI]WN>%6W5;]4&Y6OF5#;>J9S*U$A#;,I;F"#Q+1%4Q?)^UBW"L$G+QT$
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M$?HG3Q_M!+/MZ7:PI9XO=H5A!ZG.#VE(E-+#$7O-/G#8)9WZRI\T+@1_W<K
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M(DKDU:(35S!V*1L;>U O4&\$U^9ZK7,]MQYBI_@BQ<>96[-1O,5>N7[H<',
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M?WX6O)U1"9*GP:NHK#9!]\5!]WO)A/'C_MO#/W#[__CKV>M7+_X_4$L#!!0
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MDDYMU%*'_7O\G@&75Z&).Z$,,8$))B^A?!N4E7Z5Y_7JN.J%\,-,2DKZYVA
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M0S/@IFV3-0RMY%;D$5$ZX!LOJTUM#SL#FP=+&F3H-#J6<,\HMPT4!@8X]IO
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MR46(5]'ZC5"H/FF+\AS '^L8'A/JO=C>RY7G+ZZ2'Q/91KDZ;QKW=JIY$3N
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MOF-,\,]A,+*V_S]02P$"% ,4    " #9@S);C[I$%B8#  #?"P  $0
M        @ $     96YV8BTR,#(U,#DQ-RYX<V102P$"% ,4    " #9@S);
M(/O6)/T*  !_A@  %0              @ %5 P  96YV8BTR,#(U,#DQ-U]L
M86(N>&UL4$L! A0#%     @ V8,R6]YL")I9!P  TE<  !4
M ( !A0X  &5N=F(M,C R-3 Y,3=?<')E+GAM;%!+ 0(4 Q0    ( -F#,ELI
MX>X!NBP  &3Z   *              "  1$6  !E>#$P+3$N:'1M4$L! A0#
M%     @ V8,R6X,EO;..4@  %RH"  D              ( !\T(  &5X-"TQ
M+FAT;5!+ 0(4 Q0    ( -F#,ENQ<+B:]U   $$, @ )              "
M :B5  !E>#0M,BYH=&U02P$"% ,4    " #9@S);LCT,>_%1  "I$ ( "0
M            @ '&Y@  97@T+3,N:'1M4$L! A0#%     @ V8,R6]8T*5Y]
M#0  'CX   H              ( !WC@! &5X.3DM,2YH=&U02P$"% ,4
M" #9@S);3'4..AD-   '/@  "@              @ &#1@$ 97@Y.2TR+FAT
M;5!+ 0(4 Q0    ( -F#,ENI0.7Y\",  %4+ 0 +              "  <13
C 0!F;W)M."UK+FAT;5!+!08     "@ * $L"  #==P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="envb-20250917.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000890821</identifier>
        </entity>
        <period>
            <startDate>2025-09-17</startDate>
            <endDate>2025-09-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-17" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-17" id="Fact000004">0000890821</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-17" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-17" id="Fact000010">2025-09-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-17" id="Fact000011">Enveric Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-17" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-09-17" id="Fact000013">001-38286</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-17" id="Fact000014">95-4484725</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-17" id="Fact000015">Enveric Biosciences, Inc.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-09-17" id="Fact000016">245 First Street, Riverview II</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="AsOf2025-09-17" id="Fact000017">18th Floor</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-17" id="Fact000018">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-17" id="Fact000019">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-17" id="Fact000020">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-17" id="Fact000021">(239)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-17" id="Fact000022">302-1707</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-17" id="Fact000023">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-17" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-17" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-17" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-09-17" id="Fact000027">Common     stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-17" id="Fact000028">ENVB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-17" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-17" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
